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Studies on the Inhibitory Effect of Dioctyl Sodium Sulfosuccinate
on Certain Body Proteinases and Its Possible Role in Therapeutics.
Director: M. Wafik Gouda Iv\
Inhibitory effect of dioctyl sodium sulfosuccinate (DOSS), a 
medicinal surfactant, was studied on the proteinase activity of 
trypsin and pepsin in vitro, using both natural and synthetic sub­
strates. The inhibitory effect of DOSS was studied under various 
reaction conditions such as inhibitor concentration, enzyme con­
centration, substrate concentration, pH and various mixing orders 
of the components. Mechanisms of inhibition were delineated using 
initial velocity studies and various garphical techniques.
Studies with trypsin both at pH 6.4 and pH 7.6, indicate that in 
the presence of a natural substrate, substrate-inhibitor interac­
tion involving substrate depletion is the major mechanism of inhi­
bition. Some direct enzyme inhibition may also occur. In the 
presence of a synthetic substrate, a similar inhibitory mechanism 
seems to exist at pH 8.2, but at pH 6.4 a true competitive enzyme 
inhibition forms the only mechanism. Results of the dialysis 
studies indicate that DOSS interacts both with the enzyme and the 
substrate in an irreversible fashion.
Using hemoglobin, as the natural substrate, mechanistic studies 
with pepsin revealed that the antipeptic activity of DOSS is due 
to a major mechanism of substrate-inhibitor interaction. With the 
synthetic substrate, however, the inhibition of pepsin was found 
to be due to competition between the substrate and the inhibitor 
molecules for the enzyme.
Possible therapeutic significance of the inhibitory studies was 
discussed. A possible use of dioctyl sodium sulfosuccinate in the 
medical treatment of pancreatitis and peptic ulcers was suggested. 
Certain implications of the study were also discussed from the 
points of view of biopharmaceutics and drug interactions.
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CHAPTER I
INTRODUCTION
Body proteinases are molecules of relatively small size and of 
compact, nearly spherical structure- They generally are among the 
simple enzymes which are devoid of allosteric regulatory mechanisms for 
controlling the enzymatic activity. Most of them do not need any acti­
vator ions. With the exception of pepsin, most proteinases can with­
stand rather extreme conditions of pH and temperature. Reversible 
dénaturation is very common among proteolytic enzymes and one of the 
best investigated examples is the reversible dénaturation of trypsin 
(6). Proteolytic enzymes are destructive agents which could rapidly 
destroy living cells including those which manufacture them. Therefore, 
protection against the unwanted effects of these enzymes has to be pro­
vided. This is accomplished in a number of ways: (1) Manufacture of
the enzymes as inactive precursors, the so called zymogens, (2) The 
storage of the enzymes in zymogen granules whose membrane are resistant 
to proteolysis. (3) Presence of powerful and specific natural inhibi­
tors of the active enzymes. Often more than one mechanism is available 
in the living organism.
Although there is no unique way of classifying these enzymes, 
various characteristics of these enzymes have formed the basis of dif­
ferent types of classifications (17, 46, 75). Trypsin is an endopepti- 
dase with a serine residue included in the active center and belongs to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
the enzymes of animal origin. Pepsin is also an endopeptidase of animal 
origin but this enzyme unlike trypsin, belongs to the acid proteinases.
Proteolytic enzymes have many similarities in their primary 
structure in that all of them can be basically compared to the structure 
of chymotrypsinogen (45). Another important structural feature among 
these enzymes is the position of disulfide bridges, which results in a 
similar gross disposition of the polypeptide chains of these enzymes.
Reactions catalyzed by proteolytic enzymes can be divided into 
five categories as follows: (1) Hydrolysis of peptide bonds. (2) Hydrol­
ysis of amide of amino acids. (3) Peptide bond synthesis and transpepti- 
dation reactions. (4) Hydrolysis of esters of amino acids. (5) Ex­
change of oxygen between water and the carboxyl group of amino acids.
From all five of these types of reactions, hydrolysis of the peptide 
bond is the natural function of proteinases. Trypsin is maximally 
active at pH 7 and is rather specific for cleaving all peptide linkages 
in the substrate protein whose carbonyl groups are contributed by argi­
nine and lysine. Pepsin initiates hydrolysis of native proteins by 
cleaving peptide linkages in which the amino function is contributed by 
aromatic and acidic amino acids.
The theories on the role of proteolytic enzymes in physiological 
and pathological states in man and animals have been the topic of 
great controversy during the recent years. The old belief that these 
enzymes catalyze protein synthesis no longer exists, yet it would be 
equally unjustified to restrict the role of body proteinases to a few 
processes like cleavage of food proteins, mobilization of tissue pro­
teins, and protein degradation usually associated with physiological 
wear and various traumas. In fact, it is now evident that these enzymes
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
play a causative or adjunctive role in a number of disease processes 
such as inflammation, thromboembolic disorders, complement dependent 
immune reactions, peptic and duodenal ulcers, pancreatitis and even in 
some of the syndromes of malignant carcinomas (25). Trypsin and kallik- 
rein which are present in the body tissues and fluids are capable of 
releasing pharmacologically active plasma kinins (94). These proteo­
lytic enzymes play an indirect but significant role in some of the im­
portant conditions like hypertension, shock, certain pains, changed 
capillary permeability, edema, and leucocyte migration. Much evidence 
is available to support the central role of trypsin in the pathogenesis 
of pancreatitis (25, 38, 108). Direct as well as indirect evidences 
also indicate that through some yet unknown mechanism, the normal resis­
tance of the gastric mucosa to acid and pepsin is compromised in all 
peptic ulcers (50). Therefore, the role of pepsin in the pathogenesis 
of peptic ulcres seems significant ( 67, 88, 97, 106 ). In the light of 
this knowledge, the proteinase inhibitors, both synthetic and natural, 
have gained new theoretical and practical importance (108). Recently 
attempts have been made to synthesize some active site-oriented inhibi­
tors as well as to improve their inhibitory activity (11, 40, 75).
Also, it is reported that proteolytic enzymes are inhibited by agents 
such as sodium dodecyl sulfate and some sulfated polysaccharides (2,
83).
Dioctyl sodium sulfosuccinate is an anionic surfactant that is 
widely used medicinally as a fecal softener (52). The effect of this 
surfactant on drug absorption through membranes of varying complexities 
has already been reported (41, 59, 71). This agent strongly suppresses 
the ulcer formation in restrained rats when given intraduodenally (69).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Absorption of dioctylsodium sulfosuccinate into the systemic circula­
tion has been reported (28). These findings and the similarity of the 
chemical nature of this medicinal surfactant to some proteolytic inhibi­
tors such as sodium dodecyl sulfate and sulfated polysaccharides and 
protein macroanions (96, 104) led to this investigation dealing with 
the inhibitory effect of dioctyl sodium sulfosuccinate on trypsin and 
pepsin in vitro. Such an in vitro investigation was deemed to be of 
interest because of the following reasons:
1. Dioctylsodium sulfosuccinate might play an important role in the 
medical treatment of pancreatitis and peptic ulcers through its 
inhibitory effects against trypsin and pepsin respectively in vivo.
2. The recent practice of polypharmacy, i.e., prescribing drug combin­
ations has let to enormously increasing drug interactions (55, 64 
103). The simultaneous use of certain digestive enzymes like tryp­
sin and chyraotrypsin along with dioctyl sodium sulfosuccinate may 
represent such an interaction. An in vitro inhibition study would 
help in predicting and/or explaining such drug-drug interactions.
3. The pharmacological action of many prodrugs is dependent on the 
action of proteinases of the gastro intestinal tract (98). There­
fore, inhibition of these proteolytic enzymes by dioctyl sodium 
sulfosuccinate may be of significant therapeutic significance.
4. The studies of enzyme inhibitions also provide valuable information 
about the substrate specificity, the nature of the functional groups 
at the active site of the enzyme, mechanism of enzyme action and the 
participation of certain functional groups in maintaining the 
specific conformation of the enzyme molecule (66).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5. Inhibition studies provide important guidelines for the design of 
potent specific inhibitors which may prove useful therapeutic agents.
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CHAPTER II
SURVEY OF LITERATURE
Role of Body Proteinases in Physiology and Disease
Proteolytic enzymes in protein digestion. Most historical and 
one of the important physiologic functions of proteinases has been asso­
ciated with the digestion of food proteins in the gastrointestinal tract 
(73, 112). Protein digestion begins in the stomach where pepsin is 
liberated from the pepsinogen by the action of gastric hydrochloric acid. 
Pepsinogen is secreted by the chief or peptic cells of the stomach.
Human gastric mucosa has been shown (95 ) to contain three chromatograph- 
ically distinct pepsinogens which produce three different pepsins with 
slightly different properties (Pepsins I, II and III). Products of 
pepsin digestion are polypeptides of various sizes. A gelitinase that 
liquifies gelatin is also found in the stomach. Rennin is another 
enzyme of stomach responsible for milk clotting and is only found in 
young animals. Because pepsins have a pH optimum of 1.6 - 3.2, their 
action is terminated when the gastric contents are mixed with the alka­
line pancreatic juice in the duodenum. The pH of the duodenal contents 
is about 6.5. In the small intestine, small polypeptides and dipeptides 
are formed by the action of the powerful protein splitting enzymes, 
trypsin and chymotrypsin which are major enzymes of the pancreatic juice 
secreated by the exocrine portions of the pancreas. Trypsin and chymo­
trypsin are produced as their inactive zymogens trypsinogen and several 
related chymotrypsinogens. Trypsinogen is converted to active trypsin
6
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by enterokinase, an enzyme secreted by the duodenal mucosa. Enterokinase 
also seems to convert procarboxypeptidases of pancreatic juice to active 
carboxypeptidases. This enzyme contains about 41% polysaccharides that 
prevent it from being digested itself before it can exert its effect. 
Trypsin converts chymotrypsinogens into chymotrypsins. An elastase that 
hydrolyses fibrous proteins and a collagenase are also present in pan­
creatic juice. The pancreatic carboxypeptidases and the amino peptidases 
and dipeptidases of intestinal mucosa split polypeptide fragments into 
free amino acids. Amino acids may be liberated in the intestinal lumen 
or at the cell surfaces that line the luminal border of the mucosal 
cells (58, 77). Dipeptidases activities are low in the proximal part of 
the duodenum but increase rapidly in its distal part to reach maximum 
value in the jejunum and ileum (68). The rates of digestion of the 
dietary proteins vary rather widely, depending upon stomach emptying 
time, the nature of the protein, and the other food constituents ingested. 
Various enzymes involved in digestion are present in relatively large 
amounts, therefore hydrolysis per se cannot be considered as a rate 
limiting factor for absorption of amino acids (18). Thus conversion of 
many food proteins, collagen, nucleoproteins and certain endogenous pro­
teins to the free amino acids is a prominent physiological function of 
the various proteolytic enzymes of gastric, pancreatic and intestinal 
secretions.
Proteolytic enzymes in blood coagulation. Proteolytic enzymes 
also play important roles in the process of blood coagulation. For 
over a century blood clotting has been thought to involve enzymatic 
action (84). While the classical theory of coagulation considered the 
clotting factors to be enzymes circulating in an inactive or zymogen
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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form (84) some earlier investigators believed coagulation was the result 
of a physical combination or stochiometric reaction of the constituents 
C 84, 92 ). Both theories turned out to be true, when a dozen separate
plasma proteins or clotting factor activities were discovered to be in­
volved in the process of coagulation. These factors are: I, fibrinogen;
II, prothrombin; III, thromboplastin; IV, calcium; V, proaccelarin; VII, 
proconvertin; VIII, antihaemophilic factor (AHF); IX, plasma thrombo­
plastin component (PTC) or Christmas factor; X, Stuart power factor; XI, 
plasma thromboplastin antecedent (PTA); and XII, Hageman factor (84,
113). Factor la is covalently bonded or urea insoluble fibrin; Xllla is 
the activated form of the factor XIII (figrinoligase), fibrin stabiliz­
ing factor and PL is Platelet phospholipid.
The coagulation of blood results both from enzymatic and stochio­
metric reactions (56) and involves the activation of perhaps five zymogens 
to enzymes (Xlla, IXa, Xa, Ila, and Xllla) and the formation by physical 
combination of three complexes (34). The fundamental reaction in the 
clotting of blood is conversion of the soluble plasma protein fibrinogen 
to fibrin. The fibrin molecules polymerise to form a loose mesh of in­
soluble interlacing strands and this polymer is converted by the formation 
of covalent cross linkages to a dense, tight aggregate. This latter re­
action is catalyzed by factor XIII, the fibrin stabilizing factor or 
fibrinoligase, an important proteolytic enzyme. The clotting mechanism 
responsible for the formation of fibrin involves a complex series of 
reactions (Fig. 1). In this complex sequence the conversion of fibrino­
gen to fibrin is catalyzed by thrombin, another proteolytic enzyme. 
Thrombin is formed from its circulating precursor prothrombin, by the 
action of activated factor X. Factor X can be activated by reactions
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Intrinsic System
XII -> Xlla
XI
IX IXa
VIII PL
---- >
II Ila
Extrinsic System
III
VII
Xa
la (Soluble)
Xllla
la (Insoluble)
Figure 1.--Diagrammatic Summary of the Clotting mechanism.
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that proceed along either of two pathways, an intrinsic and an extrinsic 
pathway as shown in Figure 1. The complicated and repetitive pattern of 
coagulation acts as a biologic amplifier in which a several fold gain of 
activity is achieved with each stage (70). Some product of coagulation 
accelerates the development of thrombin and fibrin, hence blood clot­
ting can be termed an autocatalytic reaction. It is this chain reac­
tion pattern and explosive characteristic of blood coagulation that 
contributes to the growth of a hemostatic plug or the propagation of a 
thrombus (78).
In addition to their role in blood clotting certain proteinases 
also seem to participate in the anticlotting mechanisms of blood. Fib­
rinolytic system of the body is such a mechanism that limits clotting. 
The active component of this system is a proteolytic enzyme, plasmin or 
fibrinolysin. This enzyme not only cleaves fibrin but also attacks 
factor V, factor VIII and fibrinogen, with the liberation of substances 
that inhibit thrombin.
Proteolytic enzymes in pancreatitis. Pancreatitis can be re­
garded as a chemical autolytic process the pathogenesis of which is well 
documented from postmortem, operative and experimental studies (15).
The exact mechanism of the pathological process has yet to be estab­
lished. However, evidence is available supporting the central role of 
certain body proteinases in the pathogenesis of the disease. It has 
been reported (25) that pancreatic duct obstruction coupled with intra- 
pancreatic conversion of trypsinogen to trypsin is one of the most 
important mechanisms in the production of pancreatitis. This hypothesis 
was challenged by Beck and coworkers (14) who demonstrated that no free 
trypsin was found in hemorrhagic or necrotizing pancreatitis in dogs.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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However, this can easily be accounted by the presence of pancreatic and 
serum inhibitors. The recent reports (74) on the usefulness of specific 
trypsin inhibitors such as trasylol (trypsin inhibitor from bovine 
organ) have further strengthened the case for the importance of trypsin 
in pancreatitis.
Furthermore, some workers (22, 23, 43, 80-82) have reported 
higher levels of plasma trypsin in cancer of pancreas and acute pan­
creatitis as compared to those in the normal subjects. Nevertheless, 
contradicting reports ( 9, 10, 25 ) also prevail claiming no differences 
between the plasma trypsin levels of patients with pancreatitis and 
those of normal individuals. These controversial claims may be ex­
plained due to the fact that different groups of workers used different 
synthetic substrates. Lack of a reproducible assay which is specific 
for trypsin in human plasma or serum may obviously be another reason.
Another mechanism through which trypsin may cause pancreatitis 
may be due to its ability to liberate certain vasodepressor kinins from 
serum globulin. Evidence has been obtained that trypsin is enhanced in 
its ability to produce pancreatitis by incubation with serum (1). The 
ability of bradykinin to cause hypotension, pain, vasodilatation, in­
creased vascular permeability, smooth muscle stimulation, leucocyte 
migration, and leucocyte accumulation also suggests the possibility that 
bradykinin may play a part in a disease process such as acute haemor- 
rhagic pancreatitis, characterised by hypotension, pain, haemoconcentra- 
tion, dynamic fluid shifts, leucocytosis, edema and leucocyte infiltra­
tion of the gland ( 94 ) • This hypothesis is further supported by the 
fact that pancreas contains large quantities of trypsinogen and kallik- 
reinogen, both of which in active form, are capable of releasing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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bradykinin from its inactive precursor, bradykininogen. Bradykininogen, 
as a normal pseudoglobulin of plasma, lymph and interstitial fluid is 
readily available to the pancreas.
Two important systems related to the proteolytic release of 
pharmacologically active kinins in the body have recently been described 
( 76, 85 ). These are renin-angiotensin system and the kinin system.
Renin is the proteinase involved in the renin system and the kinin sys­
tem involves certain kininogenases, and kininases as the active enzymes. 
Plasmin and trypsin are also able to release bradykinin from their 
kininogen substrates. The particular proteolytic enzymes involved may 
be from a glandular source or of plasma.
Acute pancreatitis can also be related to the mechanism of acti­
vation of pancreatic proteinases (30). Studies on the enzyme mechanisms 
involved suggest that during activation of pancreatic proteinases, 
enterokinase converts trypsinogen into trypsin. Trypsin then reacts 
with trypsin inhibitor to form a trypsin-trypsin inhibitor complex.
After interaction with bile, trypsin inhibitor decreases and free tryp­
sin appears. Free trypsin then converts inactive zymogens of pancreas 
into active proteases. Trypsin inhibitor is thought normally to protect 
the pancreas against this premature activation within the gland. When 
trypsin inhibitor becomes depleted in a damaged pancreas (ischemia) it 
is postulated that the emerging proteinases digest the parenchyma and 
acute hemorrhagic pancreatitis results.
Trypsin also converts prophospholipase A into the active enzyme, 
phospholipase A. This enzyme splits a fatty acid off lecithin forming 
lysolecithin. Lysolecithin damages cell membranes. The cause of acute 
pancreatitis may be activation of phospholipase A in the pancreatic
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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ducts, with the formation of lysolecithin from lecithin which is a 
normal constituent of bile. This may cause disruption of pancreatic 
tissues and necrosis of surrounding fat (38).
Proteolytic enzymes in peptic ulcers. Peptic ulcers can be de­
fined as acute or chronic ulcerations of the digestive tract, occuring 
in an area accessible to gastric secretions. It is a common disorder of 
gastro intestinal tract that even today continues to be an incompletely 
understood disease. Although very little is known about the definite 
etiology of the disease, yet an interrelationship of a number of mucosal 
defensive factors and aggresive factors seems to determine an individ­
ual's susceptibility to ulcers (50, 93). Nevertheless it is important 
to note that none of these factors itself, has been shown to exert a 
strong enough effect to result in the large variations seen among various 
populations in the incidence of peptic ulcers (50). Whatever may be the 
causative factors, it has now been unequivocally established that through 
some unknown mechanism, the normal resistance of the gastric mucosa to 
acid and pepsin is compromised in all peptic ulcers (50). Some direct 
experimental evidence is available indicating the importance of pepsin 
in the pathogenesis of the disease ( 67, 88, 97, 106 ). In humans, the 
role of pepsin in gastroduodenal ulceration has been indirectly evidenced 
by the antiulcer activity shown by some macroanions which also inhibit 
peptic hydrolysis in vitro ( 96, 104). Pathophysiology of peptic ulcers 
may involve abnormalities of acid-pepsin secretion, presence of acid- 
pepsin at unusual sites or predisposition of the mucosa to ulceration 
(51). Such pathophysiological abnormalities may be a consequence of 
various physiological, anatomical, epidemiological, genetic or even 
environmental factors (38, 51).
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Weiss and Serfontein (110) have recently indicated some of the 
qualitative and quantitative biochemical differences between the ulcer­
ated tissues and the surrounding normal tissues. Compounds like hexo- 
samines, hyaluronic acid, mucopolysaccharides and the glycoproteins seem 
to be present at higher concentrations and in more reactive forms at the 
ulcerated tissue than at the normal surrounding cells.
Proteinases may play an important role in the inflammatory pro­
cess by releasing vasoactive peptides. From the fifth component of 
complement (C5) they also release a potent chemotactic factor €5%) that 
can attract macrophages and polymorphonuclear leukocytes to the site of 
inflammation. Macrophage proteinase may therefore be an important medi­
ator of parts of the chronic inflammatory process (72).
Miscellaneous. In addition to their presence in the oxyntic 
glands and the pyloric glands of the stomach, the pepsin zymogens are 
also reported to be present in the proximal deuodenum, in seminal fluid 
(of seminal viscicles origin), in amniotic fluid (probably of fetal 
origin) and in blood and urine (96). Pepsin determination either as 
uropepsin or plasma pepsin (42, 79) has been a standard clinical prac­
tice. Uropepsin values are high in duodenal ulcers and low in pernicious 
anemia. Uropepsin is decreased in cirrhosis, Addison's disease, panhy­
popituitarism, and myxedema (25). Blood pepsin seems to reflect the 
total secretory potential of the stomach (102) yet in superficial gas­
tritis with achlorhydria blood pepsin may rise due to regurgitation from 
glands blocked with inflammatory cells. The blood levels of pepsin may 
decrease if gastric atrophy predominates.
The use of chymotrypsin in opthalmology for extracting cataract 
and in certain inflammatory diseases has been reported (25). Although
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the role of trypsin in chemotherapy is controversial, the use of this 
proteolytic enzyme in pulmonary alveolar proteinosis, in promoting heal­
ing of opisitomies and certain inflammatory processes has been indicated 
(25). Small amounts of trypsin have also been reported to accelerate 
blood clotting (35).
Elastase is another pancreatic proteolytic enzyme which can con­
vert prothrombin to thrombin, thereby shortening the clotting time but 
it has no action on fibrinogen. Elastase has not been determined in 
serum but it has been claimed by certain workers that this enzyme plays 
a central role in atherosclerosis (12, 25). However, any role for this 
enzyme in human physiology and disease needs more investigations.
Certain kallikreins in the human plasma and urine have been reported 
which differ from the pancreatic kallikrein in their immunologic proper­
ties. Besides their role in the pathogenesis of pancreatitis and certain 
other inflammatory diseases, this enzyme has also been implicated in the 
production of certain aspects of malignant carcinoid syndromes (25).
Plasmin, leucine amino peptidase, carboxypeptidases A and B, 
cathepsins and certain other proteinases of human body have been re­
viewed by Colman in relation to their role in physiology, pathology and 
therapeutics (25).
Proteinase Inhibitors
Enzyme inhibition is an extensively studied field of enzymology. 
An important aspect of this work is concerned with the identification of 
active site residues and structure and function of the active center of 
enzyme. Enzyme-inhibitor interactions are also important from the point 
of view of kinetics of the reaction. The practical importance of these 
studies lies with their utility in the control of certain diseases.
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Various inhibitors of proteolytic enzymes can be classified into 
several categories according to their mode of action: (1) Inhibitors
irreversibly destroying the enzyme. (2) Noncompetitive reversible inhi­
bitors. C3) Competitive reversible inhibitors. (4) Active site direct­
ed irreversible inhibitors. (5) Specific protein inhibitors.
These proteolytic inhibitors, in particular the specific protein 
inhibitors of both synthetic and natural origin have proved very useful 
in certain diseases. Pancreatitis and peptic ulcers are two major dis­
orders among such diseases in which trypsin and pepsin respectively have 
been shown to play a central role. Therefore, important inhibitors of 
these two proteolytic enzymes are discussed as follows.
Trypsin inhibitors. A reversible competitive trypsin inhibitor 
from the extract of Ascaris lumbricoides has been isolated by Pudles 
et al (89). One microgram of the inhibitor has been found to give 100% 
inhibition of 0.5 ug of trypsin and the dissociation constant of the 
complex is 3xl0“^m. This inhibitor can also inhibit kallikrein. Along 
with trypsin inhibitor, in the ascaris extract, a pepsin inhibitor has 
also been reported. The presence of these inhibitors in Ascarides is 
thought to be a defense mechanism against the proteinases of the host 
organism.
Kunitz isolated a trypsin inhibitor form bovine pancreas (63). 
Pancreatic inhibitor is characterized by a high stability to acids, to 
heat and to pepsin. The stability decreases with increasing alkalinity. 
The isoelectric point is at pH 10 or 10.5. The inhibitor seems to form 
salts at acid pH values and is resistant to proteolytic degradation.
This inhibitor has also been referred to as bovine trypsin kallikrein 
inhibitor, polyvalent inhibitor, Kunitz inhibitor and basic pancreatic
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trypsin inhibitor. It is commercially available in highly purified form 
under the names Iniprol and Trasylol. Another trypsin inhibitor has 
been found in human, bovine and pig colostrum in an activity ratio of 
1:10:67 (108). One milliliter of pig colostrum gives 100% inactivation 
of 2 mg of trypsin. One milliliter of cows' milk gives 50% inhibition 
of the proteolytic activity of 500 pg of trypsin. The maximum inhibitor 
concentration in human milk is reached between the third and fifth day 
post partum and corresponds to the inhibition of 50-70 yg of trypsin per 
milliliter of milk. The inhibitor is stable to acid and heat. It has 
an isoelectric point at pH 4.2. A trypsin inhibiting component has been 
detected in the placenta (108) and in the amniotic fluid (108), as well 
as in the heart, lungs, and brain of various species (21, 108).
Human blood serum has been reported to contain two trypsin inhi­
bitors (16, 20, 24, 29, 32, 108). These inhibitors have been located 
to be present in the aj and U2 globulin fractions. The inhibitor from 
the a% fraction is an inhomogenous inhibitor which is unstable to heat 
and acids. It is not dializable and is precipitated by trichloroacetic 
acid. Its isoelectric point is pH 4.0. The second trypsin inhibitor 
which belongs to «2 globulin fraction, is characterized by a strong and 
instantaneous inhibiting capacity for plasmin. This inhibitor, there­
fore, is also known as a2-macroglobulin plasmin inhibitor. The inhibi­
tion is stochiometric and reversible. This inhibitor is relatively 
stable to heat and can also inhibit chymotrypsin. One milligram of 
inhibitor inhibits 17-40 pg of trypsin.
Haverback ( 47-48) found that human pancreatic juice obtained by 
drainage contained an inhibitor for trypsin and chymotrypsin which is 
soluble in trichloroacetic acid and is stable to trypsin and chymotrypsin,
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In duodenal secretion the trypsin inhibitor of pancreatic juice is de­
stroyed in the trypsin-inhibitor complex by excess trypsin, or chymo­
trypsin. The inhibitor level in the pancreatic juice can fall to mini­
mal level in experimental pancreatitis.
in chronic pancreatitis the ratio of the inhibitor to the trypsin 
in the duodenal secretion is reduced from 4.1 to 1.3 by a high protein 
diet (19). This inhibitor is different from the Kunitz's pancreatic 
inhibitor in structure and properties.
A specific trypsin inhibitor from the extracts of ovarian tumors 
has been reported (19). The inhibition of trypsin is more pronounced 
for the extracts of benign tumors than those of malignant ones. The 
nature of the inhibitor is yet poorly characterized.
Trypsin inhibitors from various bovine organs like parotid 
glands, liver and lungs have also been described. Astrup found that 
human urine contains a trypsin-inhibiting component that can be separated 
from urokinase by franctionation on calcium phosphate gel (7-8). One 
microgram of the purified inhibitor inhibits 0.83 ug of trypsin. The 
inhibitor shows practically no loss of activity at pH 2-3.5 after 30 
minutes at 100“ C. It is an acidic polypeptide, whose isoelectric point 
is pH 2.1.
An organ sepcific and sex specific trypsin inhibitor has recently 
been discovered. This inhibitor has been found in the vesicular glands 
and semen of all mammals including man (108). The inhibitor is a basic 
polypeptide which is stable to heat and acids. This inhibitor forms 1:1 
complex with trypsin and the complex formed is reversible.
A trypsin inhibitor from the submandibular and sublingular glands 
has been isolated. The inhibitor is a strongly basic polypeptide with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
19
isoelectric points of pH 12 and 12.5 (108). One microgram of inhibitor 
inhibits 3 yg of trypsin and has maximum effect between pH 7-8.
A trypsin inhibiting principle from Clostridium-botulinum and a 
trypsin inhibitor from Aspergi1lus-soyae that preferentially inhibit the 
microorgnism’s own alkaline proteinase, have been described (54, 108). 
These inhibitors need further examination in detail.
A number of useful trypsin inhibitors have also been obtained 
from various plant sources. Soybean inhibitor is the most extensively 
studied of all the natural proteinase inhibitors. Trypsin is known to 
combine with this inhibitor in a stochiometric, reversible, pH dependant 
reaction (60). It has been found to inhibit trypsin in a noncompetitive 
fashion in the presence of a natural substrate. Kinetic and thermody­
namic and other biochemical studies of the interaction between this in­
hibitor and trypsin have been so extensive that this inhibitor has become 
a model substance for inhibitory studies of trypsin.
Sohonie isolated the trypsin inhibitor from mung beans (100).
It has a molecular weight of 18,000, is relatively stable to heat and 
it inhibits trypsin stochiometrically. Crystalline trypsin inhibitors 
have also been isolated from field beans and broad beans (37, 100-101). 
Two other trypsin inhibitors of plant source have been isolated from lima 
beans and garden beans respectively. The inhibitor from the lima beans 
inhibits trypsin in a molar ratio of 1:1 and has an inhibition constant 
of 10"8m.
Vogel et al (108) recently found another trypsin inhibitor from 
beet. The inhibitor is precipitated by trichloroacetic acid; it is 
stable to acid. However, it is not stable to heat and cannot be dia- 
lyzed. One gram of beet root tissue has been shown to give 50% inhi­
bition of about 25 ug of trypsin.
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Trypsin inhibitors have also been isolated from several grains, 
e.g., whole wheat flour, cord seed, rye and wheat germ, and barley [108). 
The barley inhibitor is stable at 100° C for 15 minutes at pH 4.9 and to 
one hour's exposure to pH 2.1 at 35° C. It lias equal effect on the tryp­
tic digestion of casein, haemoglobin and certain synthetic substrates.
Various synthetic inhibitors of trypsin have also been described. 
Some of the competitive inhibitors of this kind are compounds such as 
phenyl-trans-4 amino methylcyclo hexane carboxylate, p-aminobenzamidine, 
benzaraidine, benzyl e-aminocaproate hydrochloride, thionine, 4-amino- 
methylbenzoic acid benzyl ester, proflavin, phenylguanidine, and benzyl- 
amine (75). N-a-tosyl-L-lysine chloromethyl ketone, ethyl-p-guanidino 
benzoate, broraoacetone, p-amidino-phenacyl bromide, and p-guanidino- 
phenacyl bromide are among the more important active site directed ir­
reversible inhibitors of trypsin (75). Recently a number of diamidino-a, 
w-diphenoxyalkanes have been synthesized by Geratz et al (39- 40) which 
have proved to be active site directed reversible inhibitors of trypsin 
and certain other proteinases.
Pepsin inhibitors. Pepsin is inhibited by a host of natural in­
hibitors which also inhibit trypsin and certain other proteinases (108). 
Most of these inhibitors have already been described as trypsin inhibi­
tors. However various synthetic inhibitors which specifically inhibit 
pepsin have also been synthesized (75). Among these, compounds such as 
N-acetyl-D-phenylalanayl-L-diiodotyrosine, L-phenylalanyl-L-phenylalanine 
methyl ester, and benzyloxycarbonyl-L-histidyl-L-phenylalanyl-L-phenyl 
alanine inhibit pepsin competitively (75). Although these inhibitors 
represent some of the strong inhibitory agents of pepsin, their utility 
in the disease of peptic ulcers has not been indicated.
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Among the therapeutically useful pepsin inhibitors are the macro­
anion inhibitors and certain glycopeptides as well as sulfated polysac­
charides. Some of the more important characteristics of these inhibitors 
that seem to be related to their inhibitory activity and hence their 
antiulcer action, may be described as follows: (1) These inhibitors
possess a net negative charge and the interaction of the negatively 
charged inhibitor with the positively charged protein substrate results 
in the inhibition of peptic hydrolysis. (2) Of all the physical and 
chemical parameters molecular size and degree of sulfation seem to be 
most significant in determining the antipeptic activity of the inhibitor. 
The molecule has to be a certain minimum size to show pepsin inhibitory 
activity. The inhibitory activity appears to be directly correlated with 
the sulfate content of the molecule. Antiulcerogenic activity also seems 
be to related to high sulfur content. (3) The effect of pH, order of 
addition of the reactants, ratio, and nature of the interacting species 
of different macroanions and substrates on the inhibition of peptic 
activity have been found to be important.
Bames et al ( 94 ) have shown the antipeptic effect of chondriotin 
sulfate, heparin, carragheen and dextran sulfate on peptic activity in 
vitro. They also studied the effect of these inhibitors on the mortality 
and incidence of ulcers in pylorus ligated rats. Equivalent amounts of 
heparin, carragheen and dextran sulfate produced equivalent inhibition 
of peptic activity in vitro, but dextran sulfate was more effective both 
in decreasing the mortality and the incidence of ulcers.
A number of lignosulfonates have been shown to exert antipeptic 
activity as well as antiulcerogenic effects (105, 107). Inhibition of 
peptic activity by carbonoxolone and glycyrrhetinic acid has been re­
ported by Henman (49).
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A concentration and pH dependant inhibition of pepsin by heparin, 
ribonucleic acid, chondriotin sulfate and a sulfated glycoprotein frac­
tion from human gastric juice has been shown by some workers (3, 53). 
Significant inhibitory effect on pepsin and a reduction of the occurence 
of peptic ulcers have been reported with SN-263 (sulfated amylopectin or 
depensen) and carrageenan (31).
Fogelson (36) in an uncontrolled study, treated 12 patients with 
gastric ulcer with a crude preparation of gastric mucin, which can inhi­
bit pepsin. Calcium chondriotin sulfate and paritol C have also been 
found to possess some antipeptic activity.
Cook et al (26) have reported the antipeptic and antiulcerogenic 
activity of a number of synthetic sulfated polysaccharides. They also 
correlated a number of physical and chemical parameters of these inhibi­
tors to their inhibitory effects and the antiulcerogenic activity.
The inhibition of the peptic activity of human gastric secretion 
by undegraded and degraded carrageenans of similar sulfate content has 
been examined at various pH values by Anderson and Baillie (2). These 
workers also showed the protective action of carrageenans against ex­
perimental ulcers in guinea pigs (4). Alkalies are among the most potent 
antagonists of pepsin. Any base raising the pH of the gastric juice to 
7 or above will inhibit most of the pepsin within a few seconds. Sodium 
dodecylsulfate has also been shown to significantly reduce the pepsin 
activity within 2 hours (83).
By far the most active and specific inhibitor of pepsin is pep- 
statin, which is a pentapeptide with two y-NH linkages, two B-OH groups 
and five branched aliphatic side chains. It has been reported to be 
nontoxic and is produced by Banyu Pharmaceutical Co. in Tokyo for the 
treatment of peptic ulcers (72).
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Antipeptic activity of sulfate glycopeptide has been recently 
reported by Prino et al ( 88 ). The glycopeptide was shown to inhibit 
peptic activity of human gastric juice. It aslo proved effective in 
duodenal ulcers in man and animals when tested in vivo.
Thus, most of the macroanion pepsin inhibitors have proved to be 
of significant value in peptic ulcers of animals and man. However addi­
tional well controlled clinical studies are needed to completely delin­
eate the efficacy of these inhibitors in the treatment of peptic ulcers.
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CHAPTER III 
OBJECTIVES OF RESEARCH
In spite of the fact that dioctyl sodium sulfosuccinate (DOSS) 
is widely used in medicine as fecal softener, no report is available of 
its systemic use. Probably because until recently DOSS has been claimed 
to show no absorption in the blood. Dujovne and Shoeman have now shown 
that this compound is significantly absorbed into systemic circulation 
(28). Lish (69) has shown that DOSS when administered intraduodenally 
strongly suppresses the ulcer formation in restrained rats. These find­
ings and the similarity of the chemical nature of this surfactant to 
some proteolytic inhibitors such as sodium dodecyl sulfate and sulfated 
macroanions suggested possible inhibitory effects of DOSS against tryp­
sin and pepsin. No study dealing with the inhibitory effect of DOSS 
against these enzymes has been previously reported. Since, it has been 
established that trypsin and pepsin play a central role in the patho­
genesis of pancreatitis and peptic ulcers respectively, an in vitro 
investigation of the inhibitory effect of DOSS against these proteolytic 
enzymes was deemed necessary in order to delineate the possible use of 
DOSS in pancreatitis and peptic ulcers.
The objectives of this study are the following:
1. Determination of the nature and extent of inhibitory effect of DOSS 
on trypsin and pepsin activities in vitro using both natural and 
synthetic substrates.
24
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2. To study the effect of various reaction conditions such as inhibitor 
concentration, enzyme concentration, substrate concentration, pH, 
and various mixing orders of the components.
3. To delineate the inhibitory mechanisms involved in the inhibitory 
action of DOSS against trypsin and pepsin through kinetic experi­
ments.
4. Projection of the results of the in vitro inhibitory studies to the 
more realistic in vivo situations of disease in pancreatitis and 
peptic ulcers.
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CHAPTER IV 
STUDIES WITH TRYPSIN 
I. EXPERIMENTAL
Materials
The following materials were used in these studies:
Trypsin (Beef pancreas, twice crystallized, salt free, lyophilized).
Nutritional Biochemicals Corporation.
Casein (Hammersten type).
Nutritional Biochemicals, Inc.
Na-benzoy1-DL-arginine-p-nitroanilide hydrochloride (DL-BAPNA).
Schwartz/Mann, Dickinson and Company.
Dioctyl sodium sulfosuccinate (DOSS).
"Aerosol O.T. 100%", Sargent-Welch Scientific Co.
Trizma base.
Tris (hydroxy-methyl) amino methane. Sigma Chemical Co.
Dimethyl Sulfoxide.
J. T. Baker Chemical Co.
All other chemicals used were either U.S.P. or reagent grade. 
Procedures
Methods for antitryptic activity. Two different methods for 
determining antitryptic activity were used.
Method I. Sorensen phosphate buffers (O.IM) of various pH values 
were used. A fresh 1% casein (S) solution was prepared by suspending
26
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1.0 g of casein in 100 ml of buffer and heating the suspension in a boil­
ing water bath for 15 minutes. Enzyme (E) solutions of various concen­
trations ranging between 10-50 ug per ml were prepared by first dissolv­
ing 10 mg of trypsin in 10 ml of 0.001 M HCl and then diluting with the 
appropriate buffers. Various inhibitor (I) solutions were prepared by 
dissolving required amounts of DOSS in the buffers, at appropriate pH.
The assay was carried out by a modification of Kunitz’s method
(61). In this method casein is digested under standard conditions.
The undigested casein is precipitated with trichloroacetic acid, and the 
amount of unprecipitated protein split products, which is a measure of 
the proteinase activity, is estimated spectrophotometerically in u. v. 
range. All the solutions were freshly prepared and mixed at room temp­
erature before incubation. The final volume of the digestion mixture 
was kept at 10 ml in all cases.
In this method two different mixing procedures were followed:
A. Inhibitor added to enzyme before digestion. One milliliter 
of enzyme solution was pipetted into 50 ml Erlenmeyer flasks followed by 
1 ml of the inhibitor solution. Five ml of the substrate solution was 
then added to each flask at 30 second intervals. All the flasks were 
incubated in a water bath metabolic shaker^ maintained at 37* C for one 
hour. Samples were shaken at 200 r.p.m. throughout the digestion period. 
At the end of incubation period, 3 ml of 10% trichloroacetic acid solu­
tion was added to each flask, in the same order, and allowed to stand at 
room temperature for 10 minutes. Blanks were prepared exactly in the 
same way as samples except that the casein solution was added after the 
addition of trichloroacetic acid. Both samples and blanks were then
iModel G-77, New Brunswick Scientific Co., Inc., New Brunswick, 
N. J.
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centrifuged at 8000 r.p.m. in a Sorvall SS-4 superspeed centrifuge^ for 
20 minutes and the supernatants filtered through Whatman #2 filter papers. 
The absorbance of each fiIterate was read at 280 nm against the respec­
tive blank using a Spectronic-600 spectrophotometer^. Also, controls 
were run simultaneously for every inhibition experiment. The controls 
differed from the samples in having inhibitor solution replaced by equi­
valent amounts of buffers.
The absorbance values were used as measures of reaction veloci­
ties in all the kinetic studies. The inhibition (i) equals (1-ZÎ3, 
where Vj and v represent digestion velocities with and without the inhi­
bitor respectively. Percentage inhibition values were calculated from 
values of (i).
B. Inhibitor added to substrate before digestion. The procedure 
for digestion was as in (A) above except that the inhibitor solution was 
added to the substrate first and mixed, followed by addition of enzyme.
Method II. In this method Na-benzoyl-DL-arginine-p-nitroanilide 
hydrochloride (DL-BAPNA), was used as the synthetic substrate. DL-BAPNA 
is a chromogenic substrate of trypsin and on tryptic hydrolysis releases 
p-nitroaniline which is yellow and can be estimated colorimeterically.
The procedure used was that of Erlanger et al (33) with a few modifica­
tions.
Forty-three and five tenths (43.5) milligram DL-BAPNA was dis­
solved in one ml dimethyl sulfoxide and the solution was brought to 
100 ml with 0.05 M tris buffer at pH 8.2 and containing 0.02 M CaCl2 *
Care was taken to dissolve all of the DL-BAPNA in dimethyl sulfoxide.
2jvan Sorvall, Inc., Norwalk, Conn.
3Analytical Instruments, Bausch § Lorab, Rochester, N. Y.
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Presence of any crystals caused precipitation on standing. The tempera­
ture of the stock solution was never allowed to fall below 25° C.
Various concentrations of enzyme and inhibitor solutions were prepared 
as described in Method I except that the buffers used were 0.05 M tris 
(hydroxy methyl) aminomethane buffers of various pH values.
According to the assay procedure, all the solutions were allowed 
to equilibrate at 37° C for 5 minutes before mixing. One milliliter of 
enzyme solution was pipetted into each of the 50 ml Erlenmeyer flasks, 
which were already brought to 37° C. This was followed by addition of 
1 ml of the inhibitor solution. At zero time, 5 ml of the substrate 
solution was added into each of the sample flasks. Appropriate blanks 
and controls were prepared in the same manner as described in Method I. 
Incubation of the samples, blanks and their respective controls was done 
at 37° C for 300 seconds in a water bath metabolic shaker except for 
data of Table 13, and Figure 12, in which case incubation was done for 
600 seconds. All the flasks were shaken at 100 r.p.m. throughout the 
incubation period. The reaction was stopped by adding 1 ml of 30% acetic 
acid to each flask. The final volume of the reaction mixture was kept 
at 8 ml in each case. All incubation mixtures were centrifuged and then 
filtered as described in Method I. The absorbance of the filtrates of 
both samples and blanks was recorded at 410 nm against distilled water 
using a Beckman ACTA G U I  Spectrophotometer. Difference between the 
absorbance of samples and blanks represent the proteolytic activity. 
Inhibition values (i) and the percentage inhibitions were calculated as 
described in Method I. Different orders of mixing were also carried out 
according to the two procedures used in Method I.
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Pre-incubation studies. In the pre-incubation studies the inhi­
bitor was allowed to react additionally for 15 minutes either with the 
enzyme or with the substrate before digestion was started. The controls 
were also pre-incubated for the same period of time. Digestion was car­
ried out according to Methods lA and IB.
Dialysis studies. In order to know whether the interaction of 
inhibitor towards substrate and enzyme is reversible or irreversible, 
dialysis studies were carried out at pH 6.4 and pH 7.6.
Regenerated cellulose dialysis tubings^ were cut into pieces of 
6-9 inches and thoroughly washed with distilled water. The tubings were 
then immersed in 500 ml of 10 mM sodium edetate solution and heated at 
70® - 80® C for 2 hours. After this, the tubings were allowed to cool, 
washed again thoroughly with double distilled water and stored in dis­
tilled water at 2® - 4® C in a refrigerator. Prior to use, the tubings 
were soaked in appropriate buffer for 18-24 hours.
The inhibitor was added to the enzyme or substrate and the mix­
ture incubated at 37® C for 60 minutes in a metabolic shaker at 200 r.p.m. 
A portion of the mixture was then assayed for tryptic activity using 
Method I and the rest of the mixture was put in a pre-conditioned dialy­
sis tubing sac. The sac was immersed in 1000 or 2000 ml of 0.1 M phos­
phate buffer of appropriate pH and dialysis carried out in a cold room 
at 4® C for 96 hours. The external buffer was continuously stirred with 
a stirring magnet and was replaced every 24 hours during the dialysis 
period, at the end of which the volume of the contents was measured and 
assayed for its tryptic acitivity again. No significant change in the
^No. 20, 5/8 inches in flat width for trypsin dialysis and 
No. 36, 9/8 inches in diameter for casein dialysis. Average 
pore sizes 24®A, Van-Waters and Rogers, Inc., San Francisco, 
Calif.
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Figure 2.--Effect of various inhibitor concentrations on the percentage 
inhibition of trypsin activity at pH 7.6. Ten ml of digestion mixture 
contained 10 yg enzyme (E) and 50 mg casein (S).
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Figure 3.--Effect of pH and mixing orders on percentage inhibition 
of trypsin activity. Ten ml digest contained, E=20 ug; S=50 mg; 
1=10 mg. Key: 0, inhibitor added to enzyme first; and A, inhi­
bitor added to substrate first. Substrate used was casein.
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TABLE 1
Effect of Various DOSS Concentrations on the Percentage 
Inhibition of Trypsin Activity at pH 7.6
Amount of the Components in 
10 ml of Digestion Mixture Absorbance)^ at 
280 nm against 
Respective 
Blanks
Inhibition, % of 
Control Activity
Enzyme
(yg)
Substrate^
(mg)
DOSS
(mg)
10 50 Control 0.511 “ —
10 50 1 0.423 18.0
10 50 2 0.394 23.0
10 SO 4 0.340 34.0
10 50 8 0.303 41.0
10 50 12 0.266 48.0
10 50 14 0.253 51.0
10 50 16 0.218 58.0
10 50 18 0.187 64.0
10 50 20 0.158 69.0
&Casein
^Average of at least three determinations.
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volume of the sac contents was noticed after dialysis. A control dialy­
sis experiment was run simultaneously in the same way except that the 
inhibitor solution was replaced by equivalent amount of buffer solution. 
Percentage inhibition values before and after dialysis were calculated 
as mentioned in Method I.
All the above experiments were carried out at least in duplicate.
II. RESULTS AND DISCUSSION
In all the trypsin studies, the inhibitor was added to the enzyme 
first (Mixing Order A) except for the data of Table 2 and Figure 3 in
which case both Mixing Orders A and B were used.
The inhibitory effect of DOSS on tryptic activity was studied at
various inhibitor concentrations using Method I (Table 1). A biphasic 
plot (Fig. 2) resulted on plotting the percentage inhibition against the 
inhibitor concentration. It is possible that at lower concentrations 
DOSS inhibits only by interacting with either the substrate or the enzyme 
but at higher concentrations of DOSS additional dénaturation of the pro­
tein (trypsin or casein) also takes place. The biphasic plot in Figure 2 
can also be explained as due to the saturation of either the enzyme or 
the substrate with the inhibitor. This explanation seems more likely in 
the light of the mechanistic studies to be discussed later.
The effect of pH and mixing orders on the percentage inhibition 
was also studied using Method I. The results are shown in Table 2. A 
plot of these results was made as shown in Figure 3. Figure 3 shows 
that when the inhibitor was added to the substrate first (Mixing Order 
B), the percentage inhibition remained reasonably constant throughout 
the pH range studied. When the inhibitor was added to the enzyme first
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
35
10 r
0.01 0.02 0.03
1/S
jt
0.04 0.05
Figure 4.--Plots of l/vj against 1/S for antitryptic activity 
of DOSS at two pH values. Ten ml digest contained, E=20 pg; 
1=10 mg; S=23-50 mg. Key: A pH 6.4; and 0, pH 7.6. Substrate
used was casein.
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Figure 5.— Plots of l/v^ against I for antitryptic activity of DOSS at 
pH 7.6. Key: 0, ten ml digest contained E=10 yg, S=50 mg; and A, ten
ml digest contained E=20 yg; S-50 mg. Substrate used was casein.
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Figure 6.--Plot of 1/vi against I for antitryptic activity of DOSS at 
pH 7.6. Ten ml digest contained E=30 yg; S=40 mg. Substrate used was 
casein.
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TABLE 2
Effect of pH and Mixing Orders on Percentage 
Inhibition of Trypsin Activity by DOSS 
in the Presence of a Natural 
Substrate, Casein
Amounts of Components in 
10 ml of Digestion Mixture
Inhibition^, % of 
Control Activity with
Enzyme
(ug)
Substrate
(mg)
DOSS
(mg)
pH
A B
20 SO 10 6.0 51.67 34.66
20 50 10 6.4 53.24 37.54
20 50 10 6.5 40.15
20 50 10 6.6 37.04 - -
20 50 10 6.8 32.55 33.31
20 50 10 7.2 35.64 34.38
20 50 10 7.6 31.97 32.73
20 so 10 8.0 32.25 35.15
^Average of at least four determinations, 
^Inhibitor added to enzyme first. 
^Inhibitor added to substrate first.
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TABLE 3
Effect of Different Shaking Speeds on the 
Percentage Inhibition of Trypsin 
Activity by DOSS at pH 7.6
Amounts of Components in 
10 ml of Digestion Mixture
Shaking 
Speed 
(r.p.m. )
Inhibition^, % of 
Control Activity
Enzyme
(ug)
Substrate*
(mg)
DOSS
(mg)
20 SO 10 0 32.S6
20 50 10 SO 32. OS
20 SO 10 100 32.37
20 SO 10 200 31.96
^Casein
^Average of at least five determinations.
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TABLE 4
Effect of DOSS on the Reaction Velocities of Casein Digestion 
by Trypsin at pH 7.6 at Varying Concentrations of 
Substrate and at Fixed Levels of Enzyme and Inhibitor
Serial
Amounts of Components in 10 ml 
of Digestion Mixture
Absorbance^ at 
280 nm against 
Respective Blanks
#
Enzyme, E
(ug)
Substrate, S 
(mg)
Inhibitor, I 
(mg)
Controls
(V)
With Inhibitor 
(Vi)
1 20 23 10 0.522 0.224
2 20 27 10 0.575 0.290
3 20 30 10 0.598 0.320
4 20 33 10 0.620 0.378
5 20 40 10 0.693 0.424
6 20 50 10 0.728 0.512
^Average of two determinations.
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TABLE 5
Effect of DOSS on the Reaction Velocities of Casein Digestion 
by Trypsin at pH 6.4 at Varying Concentrations of Substrate 
and at Fixed Levels of Enzyme and Inhibitor
Serial
Amounts of Components in 10 ml 
of Digestion Mixture
Absorbance® at 
280 nm against 
Respective Blanks
#
Enzyme, E 
(ug)
Substrate, S 
(mg)
Inhibitor, I 
(mg)
Controls
(V )
With Inhibitor 
Cvi)
1 20 23 10 0.368 0.116
2 20 27 10 0.392 0.145
3 20 30 10 0.432 0.168
4 20 33 10 - 0.172
5 20 40 10 0.481 0.175
6 20 SO 10 0.546 0.188
^Average of two determinations.
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TABLE 6
Effect of DOSS on the Reaction Velocities of Casein Digestion by 
Trypsin at pH 7.6 at Varying Concentrations of the Inhibitor 
and at Different Fixed Levels of Enzyme and Substrate
Serial
Amounts of Components in 
10 ml of Digestion Mixture
Absorbance^ at 280 nm against 
Respective Blanks (v^)
#
Substrate, S 
Crag)
Inhibitor, I 
(rag) A B
1 SO - 0.505 0.775
2 SO 2 0.398 0.700
3 SO 4 0.360 0.630
4 SO 8 0.318 0.600
5 SO 12 0.288 O.SOO
6 SO 14 0.280 0.460
7 SO 18 0.219 0.390
8 SO 20 0.180 0.338
^Average of two determinations. 
^Amount of enzyme used was 10 yg. 
^Amount of enzyme used was 20 yg.
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TABLE 7
Effect of DOSS on the Reaction Velocities of Casein Digestion by 
Trypsin at pH 7.6 at Varying Concentrations of the Inhibitor 
and at Different Fixed Levels of Enzyme and Substrate
Serial
Amounts of Components in 
10 ml of Digestion Mixture
Absorbance^ at 280 nm against 
Respective Blanks (vi)
#
Substrate, S 
(mg)
Inhibitor, I 
(rag) A B
1 40 —  - 0.845 0.913
2 40 1.25 0,750 0.800
3 40 2.50 0.680 0.732
4 40 5.00 0.635 0.662
S 40 10.00 0.520 0.535
6 40 20.00 0.245 0.290
^Average of at least two determinations. 
^Amount of enzyme used was 30 ug.
^Amount of enzyme used was 40 ug.
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(Mixing Order A), the resulting percentage inhibition was found to be 
significantly higher (p<0.001 as determined by the student’s t test for 
unpaired data) at pH below 6.5. This marked difference in inhibition 
pattern below pH 6.5 will be discussed later.
Data in Table 3 shows the effect of different shaking speeds on 
the antitryptic activity of DOSS at pH 7.6. In this study casein was 
used as the substrate. The results (Table 3) show that the percentage 
inhibition values remain unchanged at various shaking speeds which in­
dicates that no mechanical and/or physical forces of shear and viscosity 
are involved in the process of inhibition. Therefore, some stochiomet- 
ric chemical interactions between the various components of the reaction 
must be operative which results in the inhibitory effect of DOSS.
In order to know the mechanism of inhibition, the effect of DOSS 
on the trypsin activity at both pH 7.6 and pH 6.4 were determined using 
casein as the substrate (Tables 4-5). In these studies, the concentra­
tions of the inhibitor and the enzyme were kept constant, whereas the 
substrate levels were varied. Effect of DOSS on the reaction velocities 
of casein digestion by trypsin at pH 7.6 was also studied varying the 
concentration of the inhibitor but keeping the enzyme and the substrate 
at different fixed levels (Tables 6-7). Various graphical methods were 
used in order to delineate the particular mechanism of inhibition in­
volved.
Using the data from Tables 4 and 5, double reciprocal plots both 
at pH 6.4 and 7.6 (Fig. 4) and plots of l/v^ against I at pH 7.6 with 
different inhibitor concentrations (Fig. 5-6), indicate substrate- 
inhibitor interaction as the major mechanism of inhibition (27, 109). 
Using the data of Tables 4 and 5 plots of S/vj against S (Woolf plots).
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Figure 7.--Plot of (i) against S for antitryptic activity of DOSS at pH 
7.6. Ten ml digest contained E=20 ug; 1=10 mg. Substrate used was casein.
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Figure 8. —  Plot of (i) against S for antitryptic activity of DOSS at pH 
6.4. Ten ml digest contained E=20 yg; 1=10 mg. Substrate used was casein.
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Vi against vi/S (Hofstee plots) and plots of 1/v against l/I; plots of 
i against I from Tables 6 and 7 also yielded curves typical of substrate- 
inhibitor interaction (27, 109). Plots of fractional inhibition (i) 
against S at pH 7.6 (Fig. 7) and at pH 6.4 (Fig. 8) were made. These 
plots suggest that in addition to substrate-inhibitor interaction, 
enzyme-inhibitor interaction also contributes to the overall inhibition. 
This contribution seems to be least at pH 7.6 (Fig. 7) and most at pH 
6.4 (Fig. 8). This apparent increased involvement of the enzyme with 
the inhibitor as a consequence of a change in pH can be well explained 
by the fact that DOSS is a molecule carrying a net negative charge and 
the trypsin possesses an isoelectric point in the vicinity of pH 7.0
(62). Therefore, increased amount of inhibition below pH 6.5 is expected. 
This explains the increased inhibition below pH 6.5 observed in Figure 3. 
Also, the biphasic curve of percentage inhibition against the inhibitor 
concentration (Fig. 2), can be explained on the basis of a dual mechan­
ism of inhibition involving both the substrate and the enzyme.
Considering the fact that casein has an isoelectric point at 
pH 4.2, negatively charged DOSS cannot be expected to interact with the 
natural substrate, casein at both pH 6.4 and 7.6. However a DOSS- 
casein interaction is possible in which conformation of the natural pro­
tein, casein is changed involving no electrostatic binding,
A general inhibitory mechanism involving a substrate can be due 
to (1) substrate depletion, (2) inhibition of the enzyme by a substrate- 
inhibitor complex, (3) combination of both mechanisms. Mechanistic 
schemes, conservation equations and the various forms of the Michaelis 
equation describing these inhibitory systems have been described by 
Reiner (91) in detail. For the case where the effective concentration
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of the substrate decreases as a result of interaction with the inhibitor, 
the following scheme may be considered: 
ki
E + S C E + P
ksS + I --- => Si
'k-3
Where E, S, I, C, P and are, respectively, the concentrations of free 
enzymes, free substrate, free inhibitor, enzyme-substrate complex, pro­
duct and substrate-inhibitor complex and the k ’s are rate constants. If 
Ej., St and respectively stand for the total amounts of enzyme, sub­
strate and the inhibitor, the conservation equations for the above mech­
anism can be written as follows :
Et = E + C
St = S + S^ (Ignoring S bound in C).
It - I + Si
Considering these conservation equations and making certain mathematical 
manipulations, a very useful form of the Michaelis-Menton equation can 
be obtained as described by Reiner (91) and given below:
It = kjn
Sjti.
km_
In this equation It and St have their usual meaning as described earlier 
whereas i, Kj and are, respectively, fractional inhibition, dissocia­
tion constant for the substrate-inhibitor complex and the Michaelis 
constant. According to this equation, a plot of It against (i/l-i) must 
be hyperbolic in shape with linear asymptotes and different slopes in the 
various regions. When the variable (i/l-i) is small, the second term in 
the braces is approximately equal to (St i/l-i). Thus the initial
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Figure 9.--Plots of I against (i/l-i) for antitryptic activity 
of DOSS at pH 7.6. Key: 0, 10 ml digest contained E=20 yg;
S=50 mg; and A, 10 ml digest contained E=10 yg; S=50 mg. Sub­
strate used was casein.
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Figure 10.--Effect of incubation time on the percentage inhibition of 
trypsin activity at pH 7.6. Ten ml of digestion mixture contained 
E=10 pg; S=SO mg; and 1=10 mg. Substrate used was casein.
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TABLE 8
Effect of Pre-Incubation on Antitryptic Activity 
of DOSS at pH 7.6
Amounts of Components in 
10 ml of Digestion Mixture
Substrate/Inhibitor
Inhibition^, % of 
Control Activity
Enzyme
(yg)
Substrate^
(mg)
Inhibitor
(mg) A B C
30 40 20 2 71.0 66. 5 88.6
30 40 10 4 38.5 39.2 66.4
30 40 5 8 25.0 25.0 45.5
30 40 2.5 16 19.5 21.8 36.7
I 30 40 1.25 32 11.2 10.0 23.4
^Casein.
t*An average of two determinations.
^No pre-incubation.
®The inhibitor pre-incubated with casein for IS minutes. 
Cphe inhibitor pre-incubated with trypsin for 15 minutes.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
52
TABLE 9
Irreversible Binding of DOSS to Enzyme (Trypsin) 
and Substrate (Casein)
[
I
pH
Component 
Bound to 
the Inhibitor 
before 
Dialysis
Amount of the Components in 
10 ml of Digestion Mixture
Percentage 
Inhibition^ of 
Control Activity
Enzyme
(Pg)
Substrate
(mg)
Inhibitor
(mg)
Before
Dialysis
After
Dialysis
Trypsin 10 50 1.0 100.0 100.0
Trypsin 10 50 0.1 65.0 57.5
6.4
Trypsin 20 50 0.1 94.4 95.0
Casein 20 50 10.0 42.0 38.0
Tryspin 10 50 1.0 65.6 67.6
7.6
Casein 20 50 10.0 36.7 34.3
^Average of at least two determinations.
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TABLE 10
Effect of Incubation Time on Percentage Inhibition 
of Trypsin Activity by DOSS at pH 7.6
Amounts of Components in 
10 ml of Digestion Mixture
Incubation
Time
(Mrs)
Inhibition^, % of 
Control Activity
Enzyme
(Eg)
Substrate^
(mg)
Inhibitor
(mg)
10 50 10 0.333 57.5
10 50 10 0.666 57.3
10 50 10 1.000 55.0
10 50 10 1.333 47.6
10 50 10 1.666 41.0
10 50 10 2.000 40.4
10 50 10 2.500 39.1
^Casein.
^Average of two determinations.
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portion of the curve is linear, with slope = CK3 + 8%)Cl + S^/K^).
As (i/l-i) becomes infinite (as will be the case when i approaches 1), 
the entire second term in the braces approaches a constant. The first 
term is still linear. Hence the asymptone should be again linear, with 
slope y2 = K3 (1 + S-̂ /Kĵ ), which is smaller than the initial slope.
The shapes of such plots (Fig. 9) for dioctyl sodium sulfosuc-
cinate at pH 7.6, using casein as the substrate and resulting from Table 
6, are typical of substrate depletion. Similar plots showing substrate 
depletion as the basic mechanism were also obtained using different sub­
strate and enzyme concentrations (Table 7).
Pre-incubation studies (Table 8) show that pre-incubation of the 
substrate with the inhibitor bears no significant effect on the inhibi­
tion. Pre-incubation of the enzyme with the inhibitor prior to digestion 
seems to increase the percentage inhibition at almost all substrate/ 
inhibitor ratios. These results suggest that, besides substrate-inhibitor 
interaction, enzyme-inhibitor interaction is also a part of the overall 
mechanism of inhibition at pH 7.6. This is in good agreement with what 
has already been concluded from the mechanistic studies.
The results of the dialysis studies (Table 9) show that percent­
age inhibition values after dialysis are similar to the ones before 
dialysis, indicating no net gain in enzyme activity due to dialysis. 
Therefore, it seems that DOSS binds both casein and trypsin irreversibly 
both at pH 6.4 and pH 7.6.
Effect of incubation time on the antitryptic activity of DOSS 
was studied using Method I at pH 7.6 (Table 10). A plot of percentage 
inhibition against the incubation time was made (Fig. 10). Figure 10 
indicates an initial slow fall in the percentage inhibition, followed by
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TABLE 11
Effect of pH and Mixing Orders on the Antitryptic 
Activity of DOSS in the Presence of a 
Synthetic Substrate, DL-BAPNA
Amounts of Comnonents in 
8 ml of Reaction Mixture
pH
Percentage inhibition® 
of Control Activity with
Enzyme Substrate Inhibitor
(Pg) (mg) (Pg) A B
20 2.175 250 6.4 29.20 9.43
20 2.175 250 8. 2 27.00 12.70
^Average of at least three determinations. 
^Inhibitor added to enzyme first. 
^Inhibitor added to substrate first.
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a rapid decrease and a successive slow fall in the percentage inhibition. 
Such a continuous decrease in the percentage inhibition with time can be 
explained by considering the following simultaneous reaction taking place 
in the system;
E + S ÿ > P + E (A)
S + I ---- > SI (B)
It seems possible that in the beginning, reaction (B) proceeds at a com­
paratively faster rate (Probably due to higher affinity of the inhibitor 
for S as compared to that of E for S), followed by saturation of I with 
S to give the SI complex which is then followed by a relatively slower 
rate of reaction (A) in the forward direction [due to depletion of S and 
accumulation of products in (A)]. Such an explanation of Figure 10 is 
consistent with the mechanistic evidence and the pre-incubation studies 
discussed previously. The shape of curve in Figure 10 can also be ex­
plained by considering the following mechanism of inhibition:
E + I El
S + I  » SI
E + S --- ^ P + E
According to this mechanism a reversible enzyme-inhibitor complex is 
formed, followed by substrate-inhibitor interaction which then saturates 
and thus results into a successive decrease in percentage inhibition 
with time in Figure 10. The occurence of such a mechanism in the present 
studies is very unlikely since the results of dialysis studies indicate 
that the formation of El complex is irreversible.
The effect of mixing orders on the antitryptic activity of DOSS
was studied both at pH 6.4 and pH 8.2 using DL-BAPNA as the synthetic 
substrate (Table 11). The results suggest the involvement of an enzyme-
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Figure 11.--Plot of l/v^ against 1/S for antitryptic activity of DOSS 
at pH 8.2. Eight ml of incubation mixture contained H=40 yg; 1=0.25 mg; 
S=lxlO"G _ 5x10“^ moles. Substrate used was DL-BAPNA.
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Figure 12.--Plot of 1/v against 1/S for inhibition of trypsin activity 
by DOSS at pH 6.4. Eight ml of incubation mixture contained E=40 yg; 
S=lxlO-G - 5x10-6 moles. Key: Û, no inhibitor added; and 0, 1=0.25 mg.
Substrate used was DL-BAPNA. Both lines were drawn by the method of 
least squares. A, y=19.97 x + 1.14 (r=0.990); 0, y=35.94 x + 0.95 
(r=0.990).
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TABLE 12
Effect of DOSS on the Reaction Velocities of DL-BAPNA Hydrolysis 
by Trypsin at pH 8.2 at Varying Concentrations of the 
Substrate and at Fixed Levels of Enzyme and Inhibitor
Serial
#
Amounts of Components in 
8 ml of Reaction Mixture
Difference in Absorbance^ 
of Samples and Their 
Respective Blanks at 
410 nm Against 
Distilled Water
Enzyme, E Substrate, S Inhibitor, I Controls With Inhibitor
(yg) Cum) (ug) (V ) ( V i )
1 40 1.0 250 0.098 0.046
2 40 1.3 250 0.120 0.058
3 40 1.5 250 -- 0.065
4 40 2.0 250 0.174 0.071
5 40 3.0 250 0.191 0.084
6 40 4.5 250 - 0.090
7 40 5.0 250 0.263 ---
^Average of two determininations.
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TABLE 13
Effect of DOSS on the Reaction Velocities of DL-BAPNA Hydrolysis 
by Trypsin at pH 6.4 at Varying Concentrations of the 
Substrate and at Fixed Levels of Enzyme and Inhibitor
Serial
#
Amounts of Components in 
8 ml of Reaction Mixture
Difference in Absorbance^ 
of Samples and Their 
Respective Blanks at 
410 nm Against 
Distilled Water
Enzyme, E 
( y g )
Substrate, S 
(ym)
Inhibitor, I
( y g )
Controls
(V)
With Inhibitor 
(vi)
1 40 1.0 250 0.048 0.026
2 40 1.3 250 0.060 0.037
3 40 1.5 250 0.068 0.042
4 40 2.0 250 0.089 0.051
5 40 3.0 250 0.126 0.077
6 40 4.5 250 0.169 0.108
^Average of two determinations.
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inhibitor interaction at both pH values. However, no conclusion can be 
drawn as far as the involvement of a substrate-inhibitor interaction is 
concerned. Therefore, data for double reciprocal plots (Tables 12-13) 
were obtained using a synthetic substrate (Method II). A double reci­
procal plot (Fig. 11) at pH 8.2 indicates that the substrate-inhibitor 
interaction is the overall mechanism of inhibition, however, direct 
enzyme inhibition may also be involved. Such a mechanism was further 
confirmed to exist by making Hofstee and Woolf plots using the data of 
Table 12. This mechanism of inhibition seems to be similar to the one 
observed when casein was used as the substrate (Fig. 4). This similar­
ity in mechanisms, when two different substrates were used, may indicate 
that the interaction between the inhibitor and casein molecules involves 
some primary sites of the natural proteins. However, a double reciprocal 
plot at pH 6.4 with DL-BAPNA as substrate (Fig. 12) was found to be 
typical of a true competitive inhibition involving the enzyme-inhibitor 
interaction but no substrate-inhibitor interaction. Such a mechanism 
was further confirmed by making corresponding Woolf and Hofstee plots. 
Lack of substrate-inhibitor interaction in the presence of synthetic 
substrate at pH 6.4 may be attributed to the higher affinity of trypsin 
for DOSS which is expected at pH 6.4, considering the facts that trypsin 
has an isoelectric point of 7.0 and that DOSS assumes a net negative 
charge.
In summary, inhibition of tryptic activity by DOSS in the pres­
ence of a natural substrate, involves substrate-inhibitor interaction 
involving substrate depletion as the major mechanism at both pH 6.4 and 
pH 7,6, however some direct enzyme inhibition may also occur. Direct 
inhibitory effect of DOSS against trypsin seems to be enhanced at pH
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values below 6.5. In the presence of a synthetic substrate, at pH 8.2 
the inhibitory mechanism seems to be similar to the one outlined for 
the natural substrate, but at pH 6.4 a true competitive enzyme inhibi­
tion forms the only mechanism.
Pancreatitis is a chemical autolytic process with a well docu­
mented pathogenesis (15). Although various mechanisms underlying the 
pathological process have been reported (1, 25, 30, 38, 94) no single 
exact mechanism has been established. Nevertheless, evidence is avail­
able that trypsin plays a central role in the pathogenesis of the disease 
irrespective of the mechanism involved (22, 23, 43, 74, 80-82). It is 
then apparent that means of controlling the undesirable hypertryptic 
activity at the site of disease could serve as an approach to alleviate 
and control the disease. In fact the use of various trypsin inhibitors 
such as soybean inhibitor, ovomucoid inhibitor and trasylol, a bovine 
inhibitor (74, 108) has been reported in the treatment of pancreatitis. 
Although trasylol has found significant place as an antipancreatitis 
agent in human medicine, other inhibitors have proven effective and use­
ful only in vitro and/or in animals. Therefore in view of the various 
possible mechanisms of the disease process and even more complicated 
situation in vivo, one must exercise great care in projecting the in 
vitro data to the clinical situation. In summary, an effective and 
useful antipancreatitis agent in vivo must exhibit the following charac­
teristics: (1) The inhibitor must not be species specific and should
possess a reasonably broad inhibition spectrum. (2) Molecule should have 
a low molecular weight to permit faster diffusion into the focus of in­
flammation and should possess a membrane permeability equivalent to that 
of the enzyme molecule. (3) It should irreversibly bind the enzyme and
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should show significant inhibition in the presence of both natural and 
synthetic substrates. (4) The inhibition constant (K^) must be smaller 
than the affinity constant between the enzyme and the substrate. This 
is absolutely necessary because concentration of the enzyme to be inhi­
bited in vivo are roughly lOr? - 10"^ moles/liter. (5) The inhibitor 
must have high compatibility, nontoxicity, nonallergic and noninflam­
matory properties. (6) It should not interfere with the trypsin inhi­
biting power of plasma. (7) It should have few accessory sites of 
binding, and low rates of degradation and excretion thus ensuring higher 
bioavailabilities at the site of disease. (8) It should be appreciably 
absorbed into systemic circulation.
Although trasylol is an effective antipancreatitis agent, it has 
a very high molecular weight and inhibits reversibly with a very low 
rate of inhibition. Soybean inhibitor shows lower inhibitory effect 
with natural substrates than with synthetic ones (108). It does not 
inhibit the release of kinins by trypsin in vivo.
DOSS is a molecule with relatively lower molecular weight and is 
currently used in medicine as a fecal softener to relieve constipation 
associated with hard, dry stool. Until recently this compound has been 
generally promoted as nonabsorbable, nontoxic and a systemically inert 
pharmacological agent. However recent investigations of Dujovne and 
Shoeman (28) have shown that DOSS is considerably absorbed into the 
systemic circulation in rats and humans after its oral administration. 
Along with this finding, the present inhibitory studies with DOSS, sug­
gest a possible use of this medicinal surfactant in pancreatitis. The 
results of the present studies indicate that besides its direct inhibi­
tory effect against trypsin, the interaction of DOSS with casein may
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suggest the possibility of a similar interaction between the inhibitor 
molecule and the glycoproteins at the site of inflammation. Such an 
interaction in vivo may prove to be useful in protecting the site from 
necrosis and erosion (5). Moreover irreversible binding of DOSS with 
trypsin and casein, its smaller molecular weight as compared to protein 
inhibitors, and its excretion in bile (28) may prove to be useful charac­
teristics of DOSS as an antipancreatitis agent.
The inhibitory studies with DOSS also suggest that possible drug 
interactions may arise in the course of therapy with DOSS in situations 
and conditions where concomitant use of proteolytic enzymes like trypsin 
and chymotrypsin is desirable for the simultaneous treatment of disorders 
like indigestion, inflammation, injury, bums, pulmonary alveolar pro­
teinosis, surgery, episiotomies and blood clotting. Drug interactions 
are also possible with drug esters like penamecillin and chloramphenicol 
palmitate and certain N-acylated drugs when given orally along with DOSS. 
Such drugs are usually acted by proteinases in the gastrointestinal 
tract resulting in changed chemical and/or pharmacological activity.
These drug interactions may be difficult to recognize, particularly when 
DOSS is used as an excipient, either for the formulation of these drugs 
mentioned above or any other drug being used simultaneously.
Present studies also suggest that the use of DOSS as one of the 
adjuvants in insulin dosages may improve its oral absorption as certain 
proteinase inhibitors such as trasylol have been shown to increase in­
sulin absorption when administered together (44, 65). Such an enhance­
ment of absorption can be further augmented by the recent studies of 
Gouda (41, 59, 71) in which DOSS has been shown to enhance the absorption 
of drugs through membranes of various complexities.
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CHAPTER V 
STUDIES WITH PEPSIN
I. EXPERIMENTAL
Materials
The following chemicals were used in these studies:
Pepsin (from hog stomach mucosa, 3 x crystallized, lyophilized).
Nutritional Biochemicals Corporation.
Hemoglobin (denatured, standardized for protease assay).
Nutritional Biochemicals Corporation.
N-Acetyl-L-phenylalanyl -L-diiodotyrosine (APD).
Sigma Chemical Company.
Dioctyl sodium sulfosuccinate (DOSS).
"Aerosol 0. T. 100%", Sargent-Welch Scientific Company. 
Ninhydrin.
J. T. Baker Chemical Company.
Isopropyl alcohol (2-propanol).
J. T, Baker Chemical Company.
Methyl Cellosolve (ethylene glycol monomethyl ether).
Fisher Scientific Company.
All other chemicals used were either U.S.P. or reagent grade. 
Procedures
Methods for Antipeptic Activity. Two different methods for de­
termining the antipeptic activity were used.
65
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Method I. In this method, denatured hemoglobin is digested under 
standard conditions. The undigested hemoglobin is precipitated with tri­
chloroacetic acid, and the amount of unprecipitated protein is estimated 
spectrophotometerically in u. v. range. The method used was essentially 
that of Rajgopalan, Moore and Stein (90). However a few modifications 
in the procedure were made. The substrate, enzyme and inhibitor solu­
tions of various concentrations were prepared either in HCl (pH 1.8) or 
distilled water. All solutions were finally adjusted to pH 1.8, were 
freshly prepared and were brought to 37® C before mixing.
One milliliter of the enzyme solution was pipetted into each of 
the flasks already maintained at 37° in a metabolite water bath shaker. 
Subsequent to this 1 ml of the inhibitor solution was added to each flask 
followed by 2 ml of the substrate solution. All the samples were incu­
bated for 5 minutes at 37® C with no shaking. At the end of the incuba­
tion period, 4 ml of 5% trichloroacetic acid was added to each sample in 
the same order and thoroughly mixed. The final volume of the incubation 
mixture was kept at 8 ml in all cases. The incubation mixtures were 
allowed to remain at 37® C for 3 minutes and were then filtered through 
Whatman #2 filter paper. Blank determinations were carried out exactly 
in the same way as samples except that the substrate solution was added 
after the addition of trichloroacetic acid. The absorbance of all the 
filtrates was read at 277 nm against distilled water using a Beckman 
ACTA c m  Spectrophotometer. Controls were simultaneously run for every 
inhibition experiment. The controls differed from the samples in having 
inhibitor solution replaced by equivalent amounts of HCl (pH 1.8).
Differences between the absorbance of samples and their respec­
tive blanks represent the peptic activities and were used as measures of
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reaction velocities in all kinetic studies. Inhibition values (i) and 
the percentage inhibitions were calculated as described previously under 
Method I for antitryptic activity.
Method II. In this method, N-Acetyl-L-phenylalanyl-L-diiodo- 
tyrosine (APD) is used as the substrate. APD is a low molecular weight 
synthetic peptide that is easily hydrolysed by pepsin. The extent of 
hydrolysis is determined by measuring the ninhydrin color given by the 
newly formed L-diiodotyrosine. The assay procedure used was that of 
Jackson et al (57) with slight modifications. Various reagents used in 
this method were prepared as follows:
Enzyme and inhibitor solutions. Various concentrations of the 
enzyme and the inhibitor solutions were prepared as in Method I except 
that all the solutions were finally adjusted to pH 2.00.
Substrate solutions. The substrate was extremely difficult to 
dissolve directly at pH 2.00. Therefore, a stock solution (20x10“^M) of 
the substrate was prepared by first dissolving 12.444 mg of APD in about 
40 ml of 0.01 N NaOH solution and then adjusting the pH of the solution 
to 2.00 with HCl. Final volume of the substrate solution was made to 
100 ml with HCl at pH 2.00. Various concentrations used could be ob­
tained by further diluting the stock solution with HCl. These solutions 
were used within 30-60 minutes after preparation since material precipi­
tates on prolonged standing.
Acetate buffer (pH 5.5-5.4). Sixty-seven milliliter of glacial 
acetic acid and 360 g of sodium acetate (CH3C00Na-3H2O) were dissolved 
in 270 ml of distilled water and made up to 1000 ml with H2O.
Cyanide-acetate buffer solution. Forty-nine milligram of this 
solution was taken into a volumetric flask and made up to 1000 ml with 
more acetate buffer.
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Ninhydrin solution. Three grams of ninhydrin was dissolved in 
100 ml of methyl cellosolve (ethylene glycol monomethyl ether).
All the substrate, enzyme and inhibitor solutions were freshly 
prepared and were brought to 37* C before mixing. The final volume of 
the reaction mixture was kept at 9 ml in each case.
A series of test tubes were set up and preequilibrated at 37* C 
in a metabolic water bath. One milliliter of the enzyme solution was 
added to each tube followed by the addition of 1 ml of the inhibitor 
solution. Three milliliter of the substrate solution was then added to 
each of the tubes and the samples incubated at 37* C for 10 minutes with 
no shaking. The reaction was stopped by adding 0.5 ml of N/2 NaOH into 
each of the test tubes. All the tubes were well shaken. Five-tenths 
milliliter of cyanide-acetate buffer solution was then added to each 
tube followed by 0.5 ml additions of ninhydrin solutions. Without any 
shaking all the tubes were placed in a boiling water bath for 15 minutes, 
after which 2.5 ml of isopropylalcohol was added to each tube and allowed 
to cool at room temperature. The extent of hydrolysis was determined by 
measuring the ninhydrin color given by the newly formed L-diiodotyrosine. 
This was done by recording the absorbance of the reaction mixtures of 
both samples and blanks at 570 nm against distilled water using a Beck­
man ACTA c m  Spectrophotometer.
All blanks and controls were prepared simultaneously as described 
for Method I. The peptic activities, reaction velocities and the inhibi­
tion values were determined as indicated in Method I.
Various orders of mixing. Two different orders of mixing were 
used, namely Mixing Order A and Mixing Order B. These have already been 
described in Chapter IV. In all the pepsin studies involving Method I,
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Figure 13.— Effect of pH and mixing orders on percentage inhibition of 
pepsin. Eight ml of digest contained E=10 ug; S=2 mg; 1=200 ug. Key: 
0, inhibitor added to enzyme first; and A, inhibitor added to substrate 
first. Substrate used was hemoglobin.
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Figure 14.--Plot of 1/vi against 1/S for antipeptic activity of DOSS at 
pH 1.8. Eight ml digest contained E=10 pg; 1=200 ug; S=0.8-2.0 mg. 
Substrate used was hemoglobin.
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Figure 15.--Plot of 1/vi against I for antipeptic activity of 
DOSS at pH 1.8. Eight ml digest contained E=10 ug; 8=2 mg. 
Substrate used was hemoglobin.
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TABLE 14
Effect of Various Concentrations of DOSS on the 
Percentage Inhibition of Pepsin 
Activity at pH 1.8
Amounts of the Components 
in 8 ml of Digest
Percentage 
Inhibition^ 
of Control 
Activity
Enzyme
CPg)
Substrate^
(mg)
Inhibitor
(Pg)
4 1.2 50 -  -
4 1.2 100
4 1.2 200 72.0
4 1.2 300 100.0
4 1.2 500 100.0
4 1.2 1000 100.0
^Hemoglobin
^Average of at least three determinations.
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TABLE 15
Effect of pH and Mixing Orders on Percentage Inhibition of 
Pepsin Activity by DOSS in the Presence of a 
Natural Substrate, Hemoglobin
Amounts of Components in 
8 ml of Digest
pH
Percentage Inhibition 
Control Activity
Enzyme
(Pg)
Substrate
(mg)
Inhibitor
(yg) A B
10 2.0 200 1.5 64.40 58.10
10 2.0 200 1.8 57.20 41.00
10 2.0 200 2.1 64.90 42.50
10 2.0 200 2.4 58.20 45.20
10 2.0 200 2.7 65. 20 44.90
10 2.0 200 5.0 63.40 44.10
^Average of four determinations. 
^Inhibitor added to enzyme first. 
^Inhibitor added to substrate first.
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TABLE 16
Effect of DOSS on the Reaction Velocities of Hemoglobin 
Digestion by Pepsin at pH 1.8 at Varying Concentrations 
of Substrate and at Fixed Levels 
of Enzyme and Inhibitor
Serial
#
Amounts of Components in 
8 ml of the Digest
Difference in Absorbance® 
of Samples and Their 
Respective Blanks at 
277 nm Against 
Distilled Water
Enzyme, E
(ug)
Substrate, S 
(mg)
Inhibitor, I 
(mg)
Controls
(v)
With Inhibitor 
(Vi)
1 10 1.0 0.2 0.080 0.022
2 10 1.2 0.2 0.102 0.034
3 10 1.4 0.2 0. 124 0.054
4 10 2.0 0.2 0.184 0.085
^Average of two determinations.
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TABLE 17
Effect of DOSS on the Reaction Velocities of Hemoglobin 
Digestion by Pepsin at pH 1.8 at Various Concentrations 
of the Inhibitor and at Fixed Levels 
of Enzyme and Substrate
Serial
#
Amounts of Components in 
8 ml of the Digest Difference in Absorbance^ 
of Samples and Their 
Respective Blanks at 
277 nm Against 
Distilled Water
Enzyme, E 
(ug)
Substrate, S 
(mg)
Inhibitor, I 
(mg)
1 10 2.0 " - 0.193
2 10 2.0 0.08 0.139
3 10 2.0 0.16 0.106
4 10 2.0 0.24 0.087
5 10 2.0 0.32 0.068
6 10 2.0 0.40 0.050
^Average of two determinations.
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Mixing Order A was used except for the data of Figure 13 and Table 15 in 
which case both mixing orders were used. Only Mixing Order A was used 
in all the studies using Method II.
II. RESULTS AND DISCUSSION
The inhibitory effect of DOSS on pepsin activity was Studied at 
various inhibitor concentrations using Method I. The data is presented 
in Table 14, which shows a significant inhibitory effect at all concen­
trations above 12.5 yg/ml in the system. The effect of pH and mixing 
orders on the percentage inhibition was also studied using Method I 
(Table 15). The data was plotted as shown in Figure 13. Figure 13 shows 
a higher percentage inhibition with Mixing Order A (inhibitor added to 
the enzyme first) as compared to Mixing Order B (inhibitor added to the 
substrate first). This increase in inhibition as a consequence of mixing 
order seems to be almost constant over the pH range 1.8-3,0. However at 
pH 1.5, no significant increase in the percentage inhibition is indicated. 
The marked difference in the inhibition pattern over the pH range 1.8- 
2.0 may suggest an enzyme-inhibitor interaction taking place. This will 
be discussed later. However lack of increased inhibitory effect of DOSS 
at pH 1.5 may be accounted for by the fact that pepsin possesses a pH 
optimum range of 1.6-3.2 for its maximum activity.
The effect of DOSS on the reaction velocities of hemoglobin 
digestion by pepsin at pH 1.8 was studied using various concentrations 
of substrate (Table 16) and inhibitor (Table 17). Using these data, a 
plot of 1/vi against 1/S (Fig. 14) and a plot of l/v^ against I (Fig. 15) 
were made. Both of these plots indicate substrate-inhibitor interaction 
as the major mechanism of inhibition (27, 109). Using the data of
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Figure 16.--Plot of I against (i/l-i) for antipeptic activity of DOSS 
at pH 1.8. Eight ml digest contained E=10 ug; 8=2 mg. Substrate used 
was hemoglobin.
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Figure 17.--Plot of 1/v against 1/S for antipeptic activity 
of DOSS at pH 2.0. Nine ml of incubation mixture contained 
E=60 ug; 8=10x10-8 _ 50x10*8 moles. Key: 0, no inhibitor
added; and A, 1=50 ug. Substrate used was APD. Both lines 
were drawn by the method of least squares. A, y=22.9400 x + 
6.5500 (r=0.9900); 0, y=13.3580 x + 6.2712 (r=0.09972).
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Figure 18.— Plot of 1/vi agasint I for antipeptic activity of DOSS 
at pH 2.0. Nine ml of incubation mixture contained E=60 yg.
Key: A, 5=2.2x10“^ moles; 0, S=4.4xl0"^ moles. Substrate used
was APD. Both lines were drawn by the method of least squares.
A, y=1.4729 x + 14.694 (r=0.9948); 0, y=0.3166 x + 11.1520 (r=0.9415)
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TABLE 18
Effect of DOSS on the Reaction Velocities of APD Hydrolysis 
by Pepsin at pH 2.0 Using Various Concentrations of the 
Substrate and at Fixed Levels of Enzyme and Inhibitor
80
Serial
#
Amounts of Components in 
9 ml of Reaction Mixture
Difference in Absorbance^ 
of Samples and Their 
Respective Blanks at 
570 nm Against 
Distilled Water
Enzyme, E 
(Pg)
Substrate, S 
(20xl0-8)m
Inhibitor, I 
(Pg)
Control
(v3
With Inhibitor 
(Vi)
1 60 0.5 50 0.030 — -
2 60 0.7 50 --- 0.026
3 60 1.0 50 0.054 0.033
4 60 1.5 50 0.064
5 60 2.0 50 0.077 0.058
60 2.5 50 0.084 0.067
^Average of two determinations.
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TABLE 19
Effect of DOSS on the Reaction Velocities of APD Hydrolysis by 
Pepsin at pH 2.00 at Various Concentrations of the Inhibitor 
and at Different Fixed Levels of the Substrate and Enzyme
Serial
#
Amounts of Components in 
9 ml of Reaction Mixture
Difference in Absorbance^ 
of Samples and Their 
Respective Blanks at 
570 nm Against 
Distilled Water
Enzyme, E 
(vg)
Inhibitor, I 
(ug) A B
1 60 :-------- 0.061 0.097
2 60 25 0.044 0.077
3 60 50 0.032 0.059
4 60 75 0.024 0.057
S 60 100 0.019 0.056
^Average of two determinations.
^Amount of substrate used was (20x10"®) moles. 
®Amount of substrate used was (40x10“®) moles.
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Figure 14 and Figure 15, plots of S/vi against S, against v^/S; and 
1/i against l/I also yielded curves typical of substrate-inhibitor inter­
action (27, 109). Further characterization of this mechanism was done 
by making a plot of I against i/(l-i) (Fig. 16), which shows substrate 
depletion to be the basic mechanism involved (91).
Using the data of Figure 14, a plot of i against S was also made. 
This plot indicated that in addition to substrate-inhibitor interaction, 
enzyme inhibitor interaction may also be involved in the overall mechan­
ism of inhibition. This seems to explain the increased percentage inhi­
bition with Mixing Order A found over the pH range 1.8-3.0 in Figure 13. 
Such an additional enzyme-inhibitor interaction could have been further 
confirmed to exist through preincubation studies but such studies were 
not feasible due to the autodigestion of pepsin under the conditions as 
reported earlier (86) and also found in the present investigation.
Effect of DOSS on the reaction velocities of APD hydrolysis by 
pepsin at pH 2.00 (Method II) was studied using various concentrations 
of the substrate (Table 18) and inhibitor (Table 19). A double recipro­
cal plot (Fig. 17) was made using the data of Table 18. Figure 17 is 
typical of a true competitive inhibition due to a competition between the 
substrate and the inhibitor molecules for the similar site at the enzyme 
surface (87). Such a mechanism was further confirmed by making a plot 
of 1/v against I (Fig. 18). The value of the inhibitor constant (k^) 
was also determined from this plot (27),
From the foregoing discussion, it is apparent that DOSS interacts 
with both the substrate and the enzyme, when the substrate used is a 
natural protein, hemoglobin. On the other hand, it binds the enzyme 
molecule exclusively and shows no affinity for the substrate when the
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substrate used is a synthetic dipeptide, N-Acetyl-L-phenylelanyl-L- 
diiodotyrosine (APD). Lack of interaction between APD and DOSS and sig­
nificant interacting capacity of DOSS for hemoglobin are some of the 
typical inhibitory characteristics of the sulfated macroanion inhibitors 
of pepsin reported earlier (88). These similarities in the inhibitory 
characteristics between DOSS and macroanion inhibitors may be a conse­
quence of their structural similarities. However, the interaction be­
tween DOSS and pepsin in the presence of both a natural and a synthetic 
substrate seems to be an additional inhibitory feature of DOSS and is 
not exhibited by macroanion inhibitors (88). Such an enzyme inhibiting 
property may be attributed to higher water solubility, surface active 
properties, or a relatively lower molecular weight of DOSS. It is also 
possible that DOSS may have a molecular size and shape that highly favors 
the hydrophobic and steric considerations important in the orientation 
and proximity effects necessary for its binding to the catalytic site at 
the surface of the enzyme. The mechanistic studies also reveal that DOSS 
seems to possess a lower affinity for pepsin than for hemoglobin in the 
presence of the two. Such a behavior has also been reported to be shown 
by some macroanion inhibitors of pepsin (5). Lack of interaction between 
DOSS and APD but significant interaction between DOSS and hemoglobin, may 
also indicate the fact that DOSS probably alters the conformation of the 
natural protein, hemoglobin and no involvement of the primary structure 
takes place.
Medical treatment of peptic ulcers has been as controversial as 
the nature of the disease itself. The nature of treatments proposed 
have ranged from gastric freezing to a wide variety of possible diets to 
psychotherapy (50). Today, the most reliable clinical regimens of
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treatment depend on an elaborate group of intertwined therapeutic ap­
proaches (50). These may include rest, diet, antacids, anticholinergics, 
sedatives, tranquilizers, and psychotherapy. Although these approaches, 
when chosen and applied rationally to the individual patient, have proven 
useful in relieving symptoms and in fascilitating healing, none of these 
modes of treatment have proven effective in initiating and accelerating 
the healing of ulcers. In this regard pepsin inhibitors both direct and 
indirect have gained much significance in experimental and clinical 
ulcers (2-4, 13, 26, 31, 36, 49, S3, 72, 88, 105, 107). However these 
antiulcer agents are not capable of providing the quick symptomatic 
relief characteristic of antacids. Thus, an effective ulcer therapy has 
three aims: alleviation of the complaints, acceleration of the healing
and prevention of recurrency. The important therapeutic properties of a 
successful antiulcer agent may be outlined as follows: (1) It should
immediately neutralize the gastric hyperacidity and preferably should 
elevate the gastric pH to the range between 4 and 5. This will help in 
removal of pain and elevating the pH would ensure inactivation of exist­
ing pepsinogen and pepsin in the gastric juice. (2) A direct inhibitory 
effect on peptic activity of gastric juice. Such an action may be 
achieved through complexation, inactivation or adsorption of the active 
enzyme on the inhibitor molecule. (3) An indirect inhibitory effect of 
peptic activity which may be achieved by interaction of the inhibitor 
with one or more components which act as the natural substrates for 
pepsin. (4) The therapeutic agent must be capable of initiating the 
onset of healing. Such an effect is possible if the inhibitor can ir­
reversibly complex with the cell components of the mucosal tissue and 
thereby form an insoluble crater at the ulcerated site. Such a
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complexation will also be helpful in protecting from further necrosis 
and erosion. (5) It should decrease the gastric secretion of acid and 
pepsin that is due to vagal stimulation. (6) The therapeutic agent must 
have long gastric half life and should decrease the motility. (7) It 
should have reasonably greater buffering capacity and should also inhibit 
the release of kinins and any chemotactic factor involved in the process 
of inflammation.
Compounds like hexasosamines, hyaluronic acid, mucopolysaccha­
rides and certain glycoproteins seem to be present at higher concentra­
tion and in more reactive forms at the ulcerated tissue than at the 
normal surrounding cells (110). Many macroanion sulfated polysaccha­
rides and even some other compounds such as ulcerine, carbanoxolone 
sodium and bicitropeptide (a bismuth proteinate) have been shown to 
possess their antipeptic activity and hence their antiulcerogenic action 
due to their ability to form insoluble complexes with these tissue de­
gradation products (99, 110, 111). An ulcerated site covered with such 
a complex has been believed to be shielded from further exposure to the 
damaging effects of the acidic gastric juice and pepsin and thus result­
ing into healing of the ulcer.
In view of the mechanistic evidence, DOSS may provide a possible 
antiulcer action through such an indirect mechanism. It may also exert 
additional healing effect due to its direct inhibitory effect against 
pepsin. Pepstatin, a pentapeptide marketed by Banayu Pharmaceutical Co. 
is perhaps the most effective pepsin inhibitor in ulcers which acts 
through such a direct inhibitory action against pepsin (72). Further­
more, the findings by Lish (69) that DOSS exerts a potent inhibitory 
effect on the volume of secretions and on the amount of acid secreted
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when administered intraduodenally to rats, may further enhance the anti­
ulcerogenic effect of this compound.
A reduction in the digestive capacity of the gastric juice for 
food proteins may be a consequence of the use of DOSS as an antiulcer 
agent. Drug interactions with certain prodrugs and proteolytic enzymes 
are possible. These interactions have already been discussed in Chapter 
IV.
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CHAPTER VI
SUMMARY
Dioctyl sodium sulfosuccinate is an anionic surfactant widely 
used in medicine as a fecal softener. Inhibitory effect of this medi­
cinal surfactant on the proteinase activity of trypsin and pepsin was 
studied in vitro using both natural and synthetic substrates. The in­
fluence of various reaction conditions such as pH, mixing order, ratio 
of the components, preincubation, incubation time, and shaking rates on 
the inhibitory effect of the medicinal surfactant were studied. Kinetic 
studies were carried out using initial velocities and the mechanisms of 
inhibition were delineated employing various graphical techniques.
Mechanistic studies indicate that the inhibition of tryptic ac­
tivity by dioctyl sodium sulfosuccinate in the presence of a natural 
substrate, involves substrate-inhibitor interaction involving substrate 
depletion as the major mechanism at both pH 6.4 and pH 7.6. However some 
direct enzyme inhibition may also occur. In the presence of a synthetic 
substrate, at pH 8.2, the inhibitory mechanism seems to be similar to the 
one outlined for the natural substrate, but at pH 6.4 a true competitive 
enzyme inhibition forms the only mechanism. The interactions of the in­
hibition with the enzyme and the substrate were found to be irreversible 
through dialysis studies.
Mechanism of inhibition for pepsin was found to be similar to 
that of trypsin with the natural substrate. With the synthetic substrate,
87
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the inhibition of pepsin at pH 2.00 was also found to be due to a compe­
tition between the substrate and the inhibitor molecules for the enzyme.
Possible therapeutic significance of the inhibitory effect of 
this medicinal surfactant was discussed suggesting possible use of dioctyl 
sodium sulfosuccinate in the treatment of peptic ulcers and pancreatitis. 
Biopharmaceutical implications of the study were also discussed.
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APPENDIX
BASIC KINETIC MECHANISMS OF ENZYMES
Enzymes may be defined as the biocatalysts in the living organ­
ism. The most characteristic property and function of enzymes is the 
catalysis of chemical reaction. These reactions are complicated pro­
cesses which are made up of a series of steps involving a number of 
intermediates. Following are some of the important experimental ap­
proaches which have contributed to the present knowledge of the various 
characteristic behaviors of enzymes and the mechanisms of the reactions 
catalyzed: (1) Various protein studies related to the strtucture, size,
shape, and physicochemical properties of the enzymes. (2) Studies on 
the organic reaction models for enzyme action^. (3) Kinetic methods.
Enzyme kinetics deals with the measurement of reaction rates and 
the derivation of kinetic constants for enzyme systems. Special kinetic 
techniques like continuous flow methods, stopped flow methods, relaxa­
tion methods and temperature jump measurements can give very useful in­
formation about the enzymic catalysis in some c a s e s H o w e v e r ,  the 
types of more usual kinetic approaches^ are as follows: (1) Initial
velocity studies. (2) Inhibition studies. (3) Isotopic exchange 
studies. (4) Variation of kinetic parameters with pH. (5) Use of non­
linear reciprocal plots. (6) Use of inorganic cations.
Is. Bernhard, "The Structure and Function of Enzymes", W. A. 
Benjamin, Inc., Menlo Park, Calif., 1968.
^W. W. Cleland, In: The Enzymes. (Boyer, P. D., Vol. II, Third
Ed.) 1970, Acad. Press, N. Y., pp. 1-61.
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I. INITIAL VELOCITY STUDIES
A determination of initial velocity patterns usually involves 
variation of the concentration of one substrate at different fixed 
levels of the other components and in the absence of products. The 
normal method for determining initial velocity pattern is to use separ­
ate reaction mixture for each substrate concentration. But it is pos­
sible to determine initial velocities as a function of substrate concen­
tration from a single progress curve of the reaction if the equilibrium 
constant is high and the products do not inhibit the reaction.
In most simple enzyme systems only one of the reactants is rate 
limiting. However, more complex systems may involve more than one 
reactants, substrates, and/or intermediates which may be rate limiting. 
Kinetic equations describing such complex systems are tedious mathemati­
cal expressions. Nevertheless, rate equations of all enzyme systems can 
be reduced to one single rate equation, universally known as Michaelis- 
Menton equation^. Following is the derivation and some important 
features of Michaelis theory:
Michaelis-Menton Equation
Although it is useful to consider the rate equations of a number 
of types of possible mechanisms^, a minimum requirement for devising 
mechanisms for consideration is an understanding of the kinetic behavior 
of a given mechanism. In order to illustrate the Michaelis theory, one 
may consider the following simple type of enzymic mechanism involving a 
single intermediate:
3h . L. Segal, In: The Enzymes, (Boyer, P. D., Lardy, H. and 
Myrback, K., 2nd Ed., Vol. 1) 1959, Acad. Press, N. Y., p. 1
'̂ R. A. Alberty, Advances in Enzymology, 1 (1956).
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The mechanism
.  kg _
E + S ES P + E
' H k J -
Where E, S, ES and P are, respectively, the concentrations of free 
enzyme, free substrate, enzyme substrate complex and product and the 
k's are rate constants.
Further one may consider the following assumptions about the 
mechanism: (1) There is actually formation of an intermediate enzyme-
substrate complex, (ES). (2) Constant 'kg' is unidirectional as 'k^'
is very very small. (3) The concentration of substrate is very high as 
compared to that of enzyme, i.e., S>>E. (4) Products are released
rapidly from the enzyme. (S) Products bear no effect on the interaction 
between enzyme and substrate. (6) Concentrations of the individual com­
ponents represent the molar activities and the latter remain unaltered 
with respect to their charges in the system. (7) pH of the system does 
not change during reaction. (8) Solubilities of the reactants do not 
change during the reaction.
Velocity of the reaction "v" at any time must be:
V = kg (ES)
moreover
= ki [(E)(5)] - kz(ES) - kg (ES)d (ES) .dt
or d (ES)
dt
at steady state
d (ES)
= kiE(E)(5)] - (kg + kg) (ES) (1)
dt " u
Therefore, equation 1 can be written as:
kl [(E)(5)] = (kg + kg) (ES) (2)
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We have the conservation equation;
(Et) = (B) + (ES) Where (Et) represents total
enzyme concentration.
(E) = (Et) - (ES)
Substituting this value of (E) into Equation (2),we get: 
kl [(Et)(S) - (ES)(S)] = k2 (ES) + k3 (ES) 
or kl (Et)(S) = k2 (ES) + kg (ES) + ki (ES) (S) 
or kl (Et)(S) = (ES) [k2 + kg + ki(S)]
(ES) = kl (fj:.l(S)____
k2 + kg + ki(S)
Dividing both numerator and deniminator of R.H.S. by ki:
(Et) (S)(ES) =
(S)k1
"here "m =
Substituting this value of ES into the original equation for the 
reaction velocity:
If 'Vmax' is the maximum velocity and 
Vmax - kg(Et)
Then equation (3) becomes:
(4)(S)" Km + CS)
This is called the Michaelis and Menton Equation. According to 
this equation, a plot of v vs (S) will result in a hyperbola with an 
asymptot parallel to abscissa. In this equation represents the 
Michaelis-Menton constant. is not usually identical with the disso­
ciation constant of the enzyme-substrate complex, but rather it repre­
sents the apparent dynamic dissociation constant under steady state
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conditions. The Michaelis-Menton equation can describe the enzyme be­
havior at all the concentrations of the substrate studied. Kĵ  of a 
system may vary for different substrates, temperature, solvent, anci pH,
Km has the same units as the substrate. On the other hand Vmax ]bas the 
units of velocity and can also vary for different substrates, pH and 
temperature. 'Vmax' is dependant upon the enzyme concentration in tĥ . 
system, whereas is independant.
Some Implications of Michaelis-Menton Equation
If equation (4) would reduce to:
V = Vmax
which means that 'v' is the maximum velocity obtainable for a given 
enzyme concentration. Under these conditions, the velocity remains un­
changed for any increase in substrate concentration. This situation is 
called zero order kinetics. If (S) is 100 times K^, the deviation is li. 
When CS)<<Km, equation (4) becomes:
V . Ï S S ï j a  = V p x  = Constant (S)*Mn &m
This equation shows that velocity *v' of the reaction is directly 
proportional to substrate concentration (S). Therefore, reaction may be 
designated as of 'first order' kinetics. If (S) = 0.01 Km, the deviation 
from first order is 1%; if (S) = 0 . 1  K^, the deviation from first order 
is 9%.
Reaction rate is considered to be of mixed order for any concen­
tration of substrate between 0.1 and 10 and is described by 
equation (4).
When CS) = K^; equation (4) becomes:
V = 1/2 Vmax
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Figure 19.--Effect of substrate concentration on 
the rate of an enzyme-catalyzed reaction.
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Figure 20l--Lineweaver-Burk Plot
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which means ' equals the concentration of the substrate at which the 
reaction velocity equals half the maximum velocity obtainable.
Linear Transformations of Michaelis Equation
(1) Hyperbolic plot (Fig. 19) of v vs (S) is an inaccurate, in­
convenient and cumbersome graphical method of determining the kinetic 
parameters, Vmax and (2) High concentrations of substrate must be
used in order to obtain Vmaxî such high concentrations may not be attain­
able due to low solubility of substrate and furthermore substrate inhi­
bition may occur.
In an effort to overcome these difficulties, various linear 
transformations of the Michaelis-Menton equation have been developed. 
These may be as follows:
Lineweaver Burk Plot^. Inverting equation (4) yields;
This is an equation of a straight line with slope Km/Vmax intercept 
of ordinate, l/V^ax* A plot of 1/v vs 1/S (Fig. 20) is helpful in deter­
mining Vmax and Km conveniently. It is also informative for enzyme 
inhibition studies. But this plot is fairly insensitive at high sub­
strate concentrations. However, this problem can be overcome by 
plotting 1/v vs log .
Eadie Hofstee Plot^. Dividing both the numerator and denominator 
of R.H.S. of equation (4), by (S) yields:
^H. Lineweaver and D. Burk, J. Amer. Chem. Soc., 658 (1934). 
6g , s . Eadie, J. Biol. Chem., 146, 85 (1942).
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Slope= -Kjn
V
0 V/(S] Vmax/Km
Figure 2 L — Eadie Hofstee Plot
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Figure 2 2 --Woolf Plot
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V = .■.Ymax
1 + KmCS)
I)or V + V -7#:r = Vmax
or V = Vmax - ' Km (6)
According to this equation a plot of v vs v/(S) results in a straight 
line with the slope equal to -Km, the intercept on v/(S) axis equal to 
Vmax/Km and the intercept on v axis equal to Vmax (Fig. 21). This plot 
gives a more even distribution of the experimental points and the two 
constants appear separately. Therefore, any nonlinearity not shown by 
Lineweaver-Burk plot becomes apparent.
Woolf Plot?. Another linear transformation of equation (4) can 
be obtained by multiplying both sides of equation (5) by (S):
= & L_ + 1__ (S)
V Vmax Vmax
According to this equation a plot of (S)/v vs (S) gives a straight line 
with the slope equal to 1/Vmax> intercept on (S)/v axis equal to Km/Vmax 
and the intercept on the (S) axis equal to -Km (Fig. 22).
II. INHIBITION STUDIES
The significance of inhibition studies has already been discus­
sed. It has now been realized that rarely a kinetic mechanism can be 
worked out without extensive resort to inhibition experiments^. A com­
pound that slows down the rate of an enzyme catalyzed reaction is called
7h . Christensen and H, Palmer, "Enzyme Kinetics", W. B. Saunders 
Co., Philadelphia, 1967, p. 103.
% .  W. Cleland, In: The Enzymes, (Boyer, P. D., Vol. II, Third
Ed.) 1970, Acad. Press, N. Y., pp. 1-61.
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an inhibitor. Inhibitors usually form complexes with various enzyme 
forms and thus lower the amount of enzyme available for participation in 
the normal reaction sequence. However, inhibitors can also inhibit by 
complexing with a substrate , coenzyme or some other component on the 
system. It is possible that the substrate or products may be inhibitory 
and thus act as the inhibitors for some form of the enzyme. When a 
molecule which neither acts as a substrate nor as a product but forms 
complexes with one or more enzyme forms, is called a dead-end inhibitor. 
Inhibitory effect on the enzymic catalysis may also be exerted by an 
alternate substrate or an alternate product which may act as inhibitors. 
Dénaturation of an enzyme by general protein dénaturants is usually not 
considered as inhibition at all, but rather as protein destruction.
Most of the nonallosteric enzyme inhibitions involving enzyme- 
inhibitor interaction can be broadly classified into irreversible or 
reversible types. Irreversible inhibition usually involves the destruc­
tion or modification of one or more functional groups of the enzyme. An 
irreversible inhibitor may or may not contain structural elements of the 
substrate. If the catalytic course of an enzyme reaction involves the 
formation of metastable covalent enzyme-substrate intermediate, other 
molecules which have the ability to form similar but stable covalent 
enzymes compounds will function as irreversible inhibitors. Reversible 
inhibition on the other hand can be competitive, uncompetitive, noncom­
petitive, or even mixed types. In the competitive type, the presence of 
the inhibitor prevents the access of substrate to the catalytic site and 
the El complex is dissociable. Therefore, competitive inhibition can be 
reversed by increasing the substrate concentration. In the uncompetitive 
type of inhibition, the presence of the inhibitor at the catalytic site
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does not necessarily exclude the substrate, but the inhibitor prevents 
chemical catalytic action by the enzyme. El complex is dissociable even 
in this case. The special case of uncompetitive inhibition in which the 
presence of the inhibitor has no effect on the binding of the substrate 
to the catalytic site, is known as noncompetitive inhibition.
Distinction between these mechanisms can easily be made by using 
Lineweaver-Burk plots, i.e., plots of 1/v vs 1/S at varying concentra­
tions of inhibitor. If only the slope varies with inhibitor concentra­
tion, competitive inhibition is present. If only the intercept varies, 
one has uncompetitive inhibition. The case in which both slope and 
intercepts are function of inhibitor concentrations is termed noncompet­
itive inhibition. In truly competitive inhibition, double reciprocal 
plots are characterized by straight lines of differing slope intercept­
ing at a common intercept on the 1/v axis. In the presence of a compet­
itive inhibitor Vmax is not altered but %  is increased. In noncompet­
itive inhibition, the plots differ in slope but do not share a common 
intercept on the 1/v axis. Vmax decreases but Km may or may not remain 
unchanged in this case. In the most usual cases the slope or intercept 
variation with the inhibitor concentration is a linear function. In 
more complex cases, the slopes or intercepts give replots which are 
hyperbolas or parapolas.
Inhibitors that have the potential of interacting with the sub­
strate, may affect enzyme action. Such an inhibitor can affect the rate 
of enzyme catalyzed reaction in three ways: (a) The inhibitor may combine
with the substrate and decrease its effective concentration, (b) The in­
hibitor may combine with the substrate and the complex formed may act as 
an inhibitor for the enzyme. (c) A combination of the above two mech­
anisms .
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These types of inhibitions are frequently difficult to distin­
guish from those where apoenzyme is attacked, if the usual kinetic 
analysis is applied uncritically. The most common graphical methods 
used to distinguish such inhibitory mechanisms have been described by 
Webb^ and ReinerlO in detail. Among these methods plot of fractional 
inhibition (i) against the inhibitor concentration (I), and plots of 
I vs i/(l-i) seem to be the most important graphical techniques.
^J. L. Webb, "Enzyme and Metabolic Inhibitors", Vol. 1, Acad. 
Press, London, 1963, p. 85.
lOj. M. Reiner, "Behavior of Enzyme Systems", 2nd Ed., Van 
Nostrand Reinhold Co., N.Y., 1969, pp. 192-199.
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